<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS157280</article-id><article-id pub-id-type="doi">10.1101/2022.11.14.516465</article-id><article-id pub-id-type="archive">PPR572564</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Neuroanatomical substrates in Parkinson’s Disease psychosis and their association with serotonergic receptor gene expression: A coordinate-based meta-regression analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8532-4650</contrib-id><name><surname>Pisani</surname><given-names>Sara</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1920-9376</contrib-id><name><surname>Gunasekera</surname><given-names>Brandon</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Yining</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7542-3089</contrib-id><name><surname>Vignando</surname><given-names>Miriam</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4214-9642</contrib-id><name><surname>ffytche</surname><given-names>Dominic</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6314-216X</contrib-id><name><surname>Aarsland</surname><given-names>Dag</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2815-0505</contrib-id><name><surname>Chaudhuri</surname><given-names>K. Ray</given-names></name><degrees>MD, FRCP, DSc</degrees><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0022-5632</contrib-id><name><surname>Ballard</surname><given-names>Clive</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9120-2075</contrib-id><name><surname>Lee</surname><given-names>Jee-Young</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A8">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3282-822X</contrib-id><name><surname>Kim</surname><given-names>Yu Kyeong</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A9">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7712-930X</contrib-id><name><surname>Velayudhan</surname><given-names>Latha</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">4</xref><xref ref-type="fn" rid="FN1">^</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8688-8025</contrib-id><name><surname>Bhattacharyya</surname><given-names>Sagnik</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref><xref ref-type="fn" rid="FN1">^</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Academic Psychiatry, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE5 8AF, United Kingdom</aff><aff id="A2"><label>2</label>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE5 8AF, United Kingdom</aff><aff id="A3"><label>3</label>Centre for Neuroimaging Science, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE5 8AF, United Kingdom</aff><aff id="A4"><label>4</label>Division of Academic Psychiatry, Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE5 8AF, United Kingdom</aff><aff id="A5"><label>5</label>Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway</aff><aff id="A6"><label>6</label>Department of Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, and Parkinson’s Foundation Centre of Excellence, King’s College Hospital, London, United Kingdom</aff><aff id="A7"><label>7</label>Medical School, Medical School Building, St Luke’s Campus, Magdalen Road, University of Exeter, Exeter, EX1 2LU, United Kingdom</aff><aff id="A8"><label>8</label>Department of Neurology, Seoul National University-Seoul Metropolitan Government, Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea</aff><aff id="A9"><label>9</label>Department of Nuclear Medicine, Seoul National University-Seoul Metropolitan Government, Boramae Medical Center, 20, Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding author and address for reprints: Professor Sagnik Bhattacharyya, Department of Psychosis Studies, Box P067, Institute of Psychiatry, Psychology &amp; Neuroscience, De Crespigny Park, London SE5 8AF, UK, Tel: +44(0)20 7848 0955, Fax: +44(0)20 7848 0976, <email>sagnik.2.bhattacharyya@kcl.ac.uk</email></corresp><fn id="FN1"><label>^</label><p id="P1">Joint Senior Authors</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="preprint"><day>15</day><month>11</month><year>2022</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">CC BY-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><sec id="S1"><title>Background</title><p id="P2">Common neural underpinning of Parkinson’s Disease (PD) psychosis across different structural magnetic resonance imaging (MRI) studies remains unclear to this day with few studies and even fewer meta-analyses available.</p></sec><sec id="S2"><title>Objectives</title><p id="P3">Our meta-analysis aimed to identify and summarise studies using MRI approach to identify PD psychosis-specific brain regions and examine the relation between cortical volume loss and dopaminergic and serotonergic receptor density.</p></sec><sec id="S3"><title>Methods</title><p id="P4">PubMed, Web of Science and Embase were searched for MRI studies of PD psychosis (PDP) compared to PD patients without psychosis (PDnP). Seed-based <italic>d</italic> Mapping with Permutation of Subject Images was applied in the meta-analysis where coordinates were available. Multiple linear regressions to examine the relationship between grey matter volume loss in PDP and receptor gene expression density (extracted from the Allen Human Brain Atlas) were conducted in R.</p></sec><sec id="S4"><title>Results</title><p id="P5">We observed lower grey matter volume in parietal-temporo-occipital regions from our meta-analysis (N studies =10, PDP n=211, PDnP, n=298). These results remained significant after adjusting for PD medications and for cognitive scores. Grey matter volume loss in PDP was associated with local expression of 5-HT1a (b=0.109, <italic>p</italic>=0.012) and 5-HT2a receptors (b=-0.106, <italic>p</italic>=0.002) also after adjusting for PD medications (5-HT1a, <italic>p</italic> = 0.005; 5-HT2a, <italic>p</italic> = 0.001).</p></sec><sec id="S5"><title>Conclusions</title><p id="P6">Widespread cortical volume loss in the parieto-temporo-occipital regions involved in information processing and integration, as well as attention, could result in PD psychosis symptoms. Neurobiological mechanisms implicating serotonergic receptors may also contribute to this condition.</p></sec></abstract><kwd-group><kwd>Parkinson’s disease</kwd><kwd>psychosis</kwd><kwd>neuroanatomical correlates</kwd><kwd>meta-analysis</kwd><kwd>regional receptor density</kwd></kwd-group></article-meta></front><body><sec id="S6" sec-type="intro"><label>1</label><title>Introduction</title><p id="P7">Non-motor symptoms of Parkinson’s Disease (PD) are distressing, debilitating, and associated with poor quality of life in PD patients. Specifically, hallucinations and delusions, the key manifestations of PD psychosis (PDP), negatively impact patients and caregivers and increase care burden and risk of hospitalisation (<xref ref-type="bibr" rid="R1">Aarsland et al., 2007</xref>; <xref ref-type="bibr" rid="R45">Martinez-Martin et al., 2015</xref>). Although initially considered a by-product of dopamine augmentation treatments, evidence suggests that drug-naïve PD patients may also experience psychosis symptoms (<xref ref-type="bibr" rid="R23">Friedman, 2016</xref>; <xref ref-type="bibr" rid="R52">Pagonabarraga et al., 2016</xref>). Severity and duration of PD, dopaminergic medications, sleep disorders, cognitive decline, widespread Lewy Body pathology, and late PD onset can be risk factors for developing psychosis symptoms (<xref ref-type="bibr" rid="R7">Barrett et al., 2018</xref>; <xref ref-type="bibr" rid="R15">Chang &amp; Fox, 2016</xref>; <xref ref-type="bibr" rid="R19">Factor et al., 2014</xref>; <xref ref-type="bibr" rid="R20">Ffytche et al., 2017</xref>; <xref ref-type="bibr" rid="R79">Williams &amp; Lees, 2005</xref>).</p><p id="P8">The mechanisms underlying the emergence of psychotic symptoms in PD remain unclear. Results from structural as well as task-based and resting state magnetic resonance imaging (MRI) and positron emission tomography (PET) studies have generally reported grey matter reductions (<xref ref-type="bibr" rid="R8">Bejr-Kasem et al., 2019</xref>; <xref ref-type="bibr" rid="R24">Gama et al., 2014</xref>; <xref ref-type="bibr" rid="R51">Nishio et al., 2018</xref>; <xref ref-type="bibr" rid="R56">Ramírez-Ruiz et al., 2007</xref>) encompassing the ventral and dorsal visual pathways and hippocampus (<xref ref-type="bibr" rid="R4">Alzahrani &amp; Venneri, 2015</xref>; <xref ref-type="bibr" rid="R40">Lenka et al., 2015</xref>; <xref ref-type="bibr" rid="R81">Yao et al., 2016</xref>) as well as altered temporo-parieto-occipital activation, metabolism or functional and structural connectivity in large-scale brain networks (<xref ref-type="bibr" rid="R12">Boecker et al., 2007</xref>; <xref ref-type="bibr" rid="R30">Hall et al., 2019</xref>; <xref ref-type="bibr" rid="R32">Hepp et al., 2017</xref>; <xref ref-type="bibr" rid="R39">Lefebvre et al., 2016</xref>; Shine, Halliday, et al., 2014; <xref ref-type="bibr" rid="R67">Shine et al., 2015</xref>; <xref ref-type="bibr" rid="R72">Stebbins et al., 2004</xref>). This is consistent with a recent meta-analytic synthesis reporting fronto-temporo-parieto-occipital brain grey matter reduction in a mixed group of participants with PD and Lewy body dementia (DLB) with visual hallucinations (<xref ref-type="bibr" rid="R55">Pezzoli et al., 2021</xref>), although they did not consider the effect of potential confounders such as PD medication or concomitant symptoms, e.g., cognitive decline. Complementing this, a recent mega-analysis (<xref ref-type="bibr" rid="R75">Vignando et al., 2021</xref>) has reported extensive reduction of whole-brain cortical thickness and surface areas in visual cortex, left insula and hippocampus in PD patients with visual hallucinations compared to those without, as well as a relationship between cortical thickness loss and higher regional availability serotonergic (5-HT2a and 5-HT1a) and dopaminergic receptors (D2/D3). Collectively, these reviews focused on related different metrics of brain structure (volume, cortical thickness and surface). Meta-analyses integrating evidence regarding alterations in brain areas in PD psychosis may help unravel neuroanatomical substrates underpinning Parkinson’s psychosis. Here, we have conducted a quantitative analysis of structural neuroimaging studies investigating the neural correlates of psychosis in PD. Further, we examined whether the spatial distribution of brain structure alteration was associated with the spatial architecture of brain expression of the genes for dopaminergic (D1 and D2) and serotonergic receptors (namely 5-HT2a and 5-HT1a), the key candidate pathways implicated in PD psychosis (<xref ref-type="bibr" rid="R28">Hacksell et al., 2014</xref>). Unlike the approach adopted by <xref ref-type="bibr" rid="R75">Vignando et al. (2021)</xref> where they examined the relationship between the structural neuroimaging correlate and the density distribution data for each receptor of interest separately, we included the key candidate receptors of interest in a multiple regression model to allow investigation of their relationship with neuroimaging correlates after taking into account the effect of receptors belonging to other candidate pathways of interest.</p></sec><sec id="S7" sec-type="methods"><label>2</label><title>Methods</title><sec id="S8"><label>2.1</label><title>Search strategy and eligibility criteria</title><p id="P9">We followed (PROSPERO registration number: CRD42020221904) the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<xref ref-type="bibr" rid="R48">Moher et al., 2009</xref>) and a detailed description of the search strategy is outlined in <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 1</xref>. Studies identified from PubMed, Web of Science, Embase and the Neurosynth database were included if they examined brain alterations associated with psychosis symptoms (i.e., hallucinations and/or delusions) after PD diagnosis using different neuroimaging modalities, and a case-control design and provided brain coordinates (or available statistical maps) in standardised reference spaces, e.g., Montreal Neurological Institute (MNI) or Talairach space. There were no exclusion or restriction for this search. For this meta-analysis, we solely focused on studies that used structural magnetic resonance imaging (MRI) modality.</p></sec><sec id="S9"><label>2.2</label><title>Data extraction</title><p id="P10">Data extraction involved: study details (i.e., authors’ names, year of publications), study design, scanner characteristics (e.g., manufacturer), sample size, sample characteristics (e.g., age, gender, education levels), PD onset age, disease duration, PD symptoms, clinical measures of psychosis symptoms, cognitive measures, dopamine-replacement medications (expressed in Levodopa equivalent daily dose (LEDD)), and other clinical outcome measures (e.g., depression). Where only median values were available, this was converted into mean (<xref ref-type="bibr" rid="R41">Luo et al., 2018</xref>). Coordinates type (e.g., MNI or Talairach space), and associated <italic>t</italic> values were also extracted. Where coordinates were expressed in Talairach or other standard normalised spaces, they were converted into MNI coordinates. Authors were contacted for studies that did not report coordinate data. Data extraction was conducted independently by two researchers (SP, YL). Discrepancies were addressed through consensus or discussion with senior researchers.</p></sec><sec id="S10"><label>2.3</label><title>Data synthesis</title><p id="P11">A coordinate-based meta-analysis was conducted for structural MRI studies reporting voxel-based morphometry (VBM) results using peak coordinates and/or statistical maps by employing a random-effects approach using Seed-based <italic>d</italic> Mapping with Permutating Subject Images (SDM-PSI) (version 6.21, <ext-link ext-link-type="uri" xlink:href="https://www.sdmproject.com/">https://www.sdmproject.com/</ext-link>) (<xref ref-type="bibr" rid="R3">Albajes-Eizagirre et al., 2019</xref>). This involved computation of upper and lower bounds of effect size maps for studies based on the available peak coordinates by imputing voxel-wise effect size (<xref ref-type="bibr" rid="R2">Albajes-Eizagirre et al., 2018</xref>) and combining them with statistical parametric maps provided by the studies (where applicable) converted into effect size maps to carry out a random-effects meta-analysis. Contrasts of interest were ‘PD psychosis (PDP) &lt; PD without psychosis (PDnP)’ (i.e., grey matter loss) and ‘PD psychosis (PDP) &gt; PD without psychosis (PDnP)’ (i.e., increased grey matter) with and without controlling for the effect of PD medications (expressed in LEDD), and cognitive scores. Due to the various neurocognitive scales used to assess cognitive abilities in PDP and PDnP patients, we computed standardised scores for each study by dividing the mean score by the standard deviation (SD) for each patients’ group. Statistical parametric maps provided by the studies (where applicable) were registered to the SDM template, and their <italic>t</italic> values were converted into effect sizes and included in the analysis. SDM-PSI provides <italic>I<sup>2</sup></italic> statistic to assess heterogeneity in the observed peaks as well as between-study heterogeneity (<xref ref-type="bibr" rid="R33">Higgins et al., 2003</xref>). Funnel plots for each peak and Egger’s test (<xref ref-type="bibr" rid="R18">Egger et al., 1997</xref>) were used to assess publication bias. Clusters smaller than 10 voxels were discarded.</p><p id="P12">We examined the association between grey matter volume loss (measured using Hedges’ <italic>g</italic> effect-size estimates extracted from the centroid of the SDM-PSI meta-analytic map parcellated across 78 brain regions of the Desikan-Killiany atlas (<xref ref-type="bibr" rid="R17">Desikan et al., 2006</xref>)) in PDP compared to PDnP patients with dopaminergic (D1/D2) and serotonergic (5-HT2a/5-HT1a) mRNA microarray gene expression using a multiple linear regression analysis. A secondary analysis included LEDD as a covariate when computing Hedges’ g effect-size estimate. Gene expression data for dopaminergic and serotonergic receptors was extracted from the Allen Human Brain Atlas which includes microarray expression data in tissue samples from six healthy adult human brains with more than 20,000 genes quantified across cortical and subcortical regions, including brainstem and cerebellum (<xref ref-type="bibr" rid="R31">Hawrylycz et al., 2012</xref>). Probe-to-gene re-annotation data was downloaded using the information from <xref ref-type="bibr" rid="R6">Arnatkeviĕiūtė et al. (2019)</xref>. Sample-to-region matching, and extraction of the gene expression data followed established approaches (<xref ref-type="bibr" rid="R6">Arnatkeviĕiūtė et al., 2019</xref>; <xref ref-type="bibr" rid="R43">Markello et al., 2021</xref>). Gene expression data for D3 receptor could not be matched to the probe and therefore was not extracted.</p></sec><sec id="S11"><label>2.4</label><title>Quality rating assessment</title><p id="P13">Study quality was assessed with the Newcastle-Ottawa rating Scale (<xref ref-type="bibr" rid="R78">Wells et al., 2000</xref>) for case-control studies. This scale includes three methodological domains: “Selection” (i.e., definitions of cases and controls, and their selection), “Comparability” (i.e., comparison of cases and controls on the variables of interest, inclusion of covariates), and “Exposure” (i.e., how exposure such as condition was defined and ascertained). This rating is based on a star system: studies can be awarded a maximum of one star for each “Selection” and “Exposure” items, and a maximum of two stars for the “Comparability” domain. Quality ratings were conducted by one researcher. In this review, neural substrates of PDP patients were compared to those in PDnP patients, thus the latter acted as control or comparison group. Therefore, the items “Selection of controls” and “Definition of controls” were specifically related to PDnP patients.</p></sec></sec><sec id="S12" sec-type="results"><label>3</label><title>Results</title><sec id="S13"><label>3.1</label><title>Study characteristics</title><p id="P14">Our systematic search identified 14 studies out of which 9 reported peak coordinate data, and one provided T maps (<xref ref-type="bibr" rid="R8">Bejr-Kasem et al., 2019</xref>; <xref ref-type="bibr" rid="R9">Bejr-Kasem et al., 2020</xref>; <xref ref-type="bibr" rid="R21">Firbank et al., 2018</xref>; <xref ref-type="bibr" rid="R26">Goldman et al., 2014</xref>; <xref ref-type="bibr" rid="R37">Lawn, 2021</xref>; <xref ref-type="bibr" rid="R38">Lee et al., 2017</xref>; <xref ref-type="bibr" rid="R53">Pagonabarraga et al., 2014</xref>; <xref ref-type="bibr" rid="R56">Ramírez-Ruiz et al., 2007</xref>; <xref ref-type="bibr" rid="R64">Shin et al., 2012</xref>; <xref ref-type="bibr" rid="R77">Watanabe et al., 2013</xref>). Thus, we included a total of 10 published articles (<xref ref-type="fig" rid="F1">Fig. 1</xref>) reporting on a total of n= 211 PDP (mean age ± SD = 69.01 ± 4.90; motor symptom score, mean ± SD = 28.72 ± 11.69, LEDD mg/day mean ± SD = 651.9 ± 318.14) and n=298 PDnP patients (mean age ± SD = 67.34 ± 4.59, motor symptom scores, mean ± SD = 25.94 ± 8.63, LEDD mg/day mean ± SD = 577.1 ± 263.11) (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p id="P15">Full quality ratings are reported in <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 2</xref> (eTable1). Briefly, all studies had full score on the “Exposure” domain (i.e., ascertainment, non-response rate and ascertainment method for PDP and PDnP patients); “Comparability” was good in all studies due to their matched design, whereby patients were matched on age, gender and other clinical or demographic variables, whilst other studies reported these variables as covariates in the analysis. “Selection” domain included selection and definition of both PDP patients (i.e., cases) and PDnP patients (i.e., controls), selection of PDP patients was assigned one star (i.e., the maximum) in all studies. Similarly, selection of PDnP patients was assigned one star in all studies, whilst definition of such group was clear in one study which was assigned one star in this domain.</p></sec><sec id="S14"><label>3.2</label><title>Meta-analysis: Voxel-based morphometry (VBM)</title><p id="P16">Meta-analysis of 10 MRI studies (one provided statistical maps (<xref ref-type="bibr" rid="R38">Lee et al., 2017</xref>)) showed that PDP patients had reduced grey matter volume in parietal-temporo-occipital areas compared to PDnP patients with the largest clusters located in the right precuneus (extending to left precuneus and bilateral cuneus; voxel number = 1059, Z=-2.990, <italic>p</italic> = 0.001), bilateral inferior parietal gyrus (left inferior parietal gyrus, extending to left angular gyrus and supramarginal gyrus; voxel number = 296, Z=-2.449, <italic>p</italic> = 0.007; right inferior parietal gyrus, extending to right angular gyrus; voxel number = 277, Z=-2.225, <italic>p</italic> = 0.013), left inferior occipital gyrus (voxel number = 262, Z =-2.627, <italic>p</italic> =0.004), and right middle temporal gyrus (extending to right inferior temporal gyrus; voxel number = 225, Z = -2.664, <italic>p</italic> = 0.003) (eFigure1, <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 3</xref>). We did not observe any significant peaks in the opposite direction (i.e., ‘PDP &gt; PDnP’). Neither between-study heterogeneity as a proportion of total variability (all <italic>I<sup>2</sup></italic> statistic &lt;25%, except right inferior parietal gyrus, which was ~27.6%) nor publication bias was observed in these peaks (Funnel plots in <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 3</xref>). However, none of these brain regions survived correction for multiple testing. After including PD medication dose, expressed LEDD, as a covariate, grey matter reduction in right precuneus remained significant in PDP patients compared to PDnP patients (extending to left precuneus, and bilateral cuneus; voxel number = 1084, <italic>Z</italic> = -2.952, <italic>p</italic> = 0.001). There was substantial overlap between previously identified peaks, with the largest clusters in the left angular gyrus (extending to left inferior parietal gyrus; voxel number = 389, <italic>Z</italic>=-2.596, <italic>p</italic> = 0.004), right inferior temporal gyrus (extending to right middle temporal gyrus and right fusiform; voxel number = 353, <italic>Z</italic> =-.2921, <italic>p</italic> = 0.001), the left middle occipital gyrus (extending to inferior occipital gyrus; voxel number = 315, <italic>Z</italic>=-2.902, <italic>p</italic> = 0.001), and the right inferior parietal gyrus (extending to right angular gyrus; voxel number = 304, <italic>Z</italic>=-2.525, <italic>p</italic> = 0.005) (eFigure2, <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 3</xref>). No publication bias was observed in any of these analyses (Funnel plots in <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 3</xref>). However, none of these brain regions survived correction for multiple testing. When cognitive scores were entered as covariate, the right precuneus remained the largest cluster showing grey matter volume reduction (extending to the left precuneus, bilateral cuneus, voxel number = 1186, <italic>Z</italic> = -3.287, <italic>p</italic> &lt; 0.001). In addition, this analysis showed other areas of lower grey matter volume in PDP compared to PDnP patients were observed. These were the left inferior occipital gyrus (extending to the middle occipital gyrus and left optic radiation, voxel number = 252, <italic>Z</italic> = −2.508, <italic>p</italic> = 0.006), the left postcentral gyrus (extending to the left precuneus, voxel number = 116, <italic>Z</italic> = -2.358, <italic>p</italic> = 0.009), and the right superior parietal gyrus (voxel number = 28, <italic>Z</italic> = -2.030, <italic>p</italic> = 0.021) (eFigure3, <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 3</xref>). No publication bias was observed in any of these analyses (Funnel plots in <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 3</xref>). The overlap between brain regions across the unadjusted and adjusted analyses is shown in <xref ref-type="fig" rid="F2">Figure 2</xref>, and <xref ref-type="table" rid="T2">Table 2</xref> reports peaks coordinates from the three analyses. We did not observe any significant peak in the opposite direction (i.e., ‘PDP &gt; PDnP’) in either LEDD- or cognitive score-adjusted analyses. None of the areas across the three analyses survived familywise error correction.</p></sec><sec id="S15"><label>3.3</label><title>Whole brain correlations with D1/D2 and 5-HT2a/5-HT1a gene expressions</title><p id="P17">Due to presence of multicollinearity in the multiple linear regression model, D2 receptor data were dropped from the analysis (i.e., due to a variation inflation factor, VIF = 6.5). Multiple linear regression analysis showed a significant association between Hedges’ <italic>g</italic> effect-size estimates of grey matter volume unadjusted for LEDD and 5-HT2a gene expression (regression coefficient =-0.107 (95% CI, -0.174, -0.039), t=-3.147, <italic>p</italic> = 0.002) and 5-HT1a gene expression (regression coefficient = 0.109 (95% CI, 0.024, 0.193), t = 2.565, <italic>p</italic> = 0.012) but not with D1 gene expression (D1, <italic>p</italic> = 0.554) across the 78 regions of the Desikan-Killiany atlas. Separate analysis with Hedges’ <italic>g</italic> effect-size estimates for grey matter volume adjusted for LEDD did not change the result (5-HT2a, regression coefficient =-0.120, 95% CI -0.190, -0.050, t=-3.408, <italic>p</italic>=0.001; 5-HT1a, regression coefficient =0.126, 95% CI 0.038, 0.213, t=2.848, <italic>p</italic>=0.006; D1, <italic>p</italic>=0.597). Presence of multicollinearity was also detected in this model and D2 was removed (VIF=6.67). <xref ref-type="fig" rid="F3">Figure 3</xref> reports the association between grey matter volume loss and receptor density from the LEDD-adjusted analysis. In both multiple linear regression models (adjusted and unadjusted for LEDD), the associations between regional cortical volume and serotonergic gene expressions were consistent in terms of direction of relationship. However, these associations were in opposite directions for the two serotonergic receptors, whereby the less the grey matter volume the more the 5-HT2a gene expression density and the less the 5-HT1a gene expression density across the 78 regions of the Desikan-Killiany atlas. That is, the greater the grey matter reduction the greater the 5-HT2a and the lower 5-HT1a gene expression density. Figures showing the relationship between cortical and subcortical spatial gene expressions and Hedges’ <italic>g</italic> effect sizes unadjusted for LEDD are in <xref ref-type="supplementary-material" rid="SD1">Supplementary Material 4</xref> (eFigure4-5).</p></sec></sec><sec id="S16" sec-type="discussion"><label>4</label><title>Discussion</title><p id="P18">Findings from individual studies reported extensive areas of lower grey matter volume in PDP without providing clear understanding on whether PDP may be due to structural issues in key regions or diffused anomalies. Here, we have addressed this ambiguity by incorporating results from structural MRI studies using a quantitative approach to identify neuroanatomical correlates implicated in PDP. The meta-analytic results found widespread grey matter volume reduction across parietal-temporal-occipital regions in PDP patients, specifically, the right precuneus (extending to the left precuneus), bilateral inferior parietal gyrus, and left inferior occipital gyrus, corroborating previous evidence (<xref ref-type="bibr" rid="R26">Goldman et al., 2014</xref>; <xref ref-type="bibr" rid="R40">Lenka et al., 2015</xref>; <xref ref-type="bibr" rid="R80">Yao et al., 2014</xref>). Volume reduction in right precuneus, bilateral inferior parietal gyrus, left median cingulate/paracingulate cortex, and right inferior and middle temporal gyrus remained significant and was independent of PD medications and cognitive scores. When PD medications and cognitive scores standardised across studies were included as a covariate, there were additional areas of lower cortical volume within occipital (e.g., left middle occipital gyrus), parietal (e.g., right lingual and left angular gyrus), and temporal regions (e.g., right fusiform gyrus). These results also extend on previous evidence (<xref ref-type="bibr" rid="R8">Bejr-Kasem et al., 2019</xref>; <xref ref-type="bibr" rid="R36">Jia et al., 2019</xref>; <xref ref-type="bibr" rid="R40">Lenka et al., 2015</xref>; <xref ref-type="bibr" rid="R80">Yao et al., 2014</xref>). Across the analyses, we identified large clusters of grey matter loss in regions associated with higher order visual processing (i.e., dorsal and ventral visual pathways) and the Default Mode Network (DMN), and specifically the precuneus, one of the DMN nodes, which is embedded in the parietal lobe and is involved in information processing (including visual information) (<xref ref-type="bibr" rid="R13">Buckner et al., 2008</xref>; <xref ref-type="bibr" rid="R14">Cavanna &amp; Trimble, 2006</xref>; <xref ref-type="bibr" rid="R22">Freton et al., 2014</xref>; <xref ref-type="bibr" rid="R29">Hafkemeijer et al., 2012</xref>; <xref ref-type="bibr" rid="R40">Lenka et al., 2015</xref>). Grey matter volume loss in these areas may lead to dysfunctional information integration giving rise to visual hallucinations in PD patients, and also potentially due to an overreliance on endogenous attentional mechanisms (<xref ref-type="bibr" rid="R66">Shine et al., 2011</xref>; Shine, O’Callaghan, et al., 2014) as suggested by the involvement of DMN nodes (<xref ref-type="bibr" rid="R58">Rektorova et al., 2014</xref>).</p><p id="P19">Furthermore, this review expands on previous evidence by investigating the association between regional grey matter volume (as measured by Hedges’ <italic>g</italic> effect-size estimates from the meta-analysis) and key candidate receptors involved in PDP as indexed by mRNA microarray gene expression extracted from the Allen Human Brain Atlas (<xref ref-type="bibr" rid="R31">Hawrylycz et al., 2012</xref>). Expression of 5-HT2a and 5-HT1a receptors were associated with estimates of grey matter volume, albeit being in opposite direction. Whether the inverse relationship observed here between pooled grey matter volume in PDP patients and the pooled expression of 5-HT2a receptors in an independent healthy cohort indicates that in PDP patients the greater the grey matter volume loss the greater is the regional 5-HT2a receptor availability, remains to be tested by direct investigation using both imaging modalities in the same group of participants. Nevertheless, if an association between grey matter loss in PDP and increased 5-HT2a receptor availability is demonstrated in PDP, it would be consistent with pharmacological evidence of the efficacy of the atypical antipsychotic Pimavanserin, a highly selective 5-HT2a receptor antagonist, in the treatment of psychosis in PD (<xref ref-type="bibr" rid="R42">Majlath et al., 2017</xref>; <xref ref-type="bibr" rid="R46">Meltzer et al., 2010</xref>; <xref ref-type="bibr" rid="R47">Mohanty et al., 2019</xref>; <xref ref-type="bibr" rid="R70">Stahl, 2016a</xref>; <xref ref-type="bibr" rid="R82">Yunusa et al., 2020</xref>). On the other hand, the direct relationship between grey matter volume and the pooled expression of 5-HT1a receptors, may indicate that in PDP patients the lower the grey matter volume the lower the regional availability of 5-HT1a receptors. Whether this holds true when investigated using both imaging modalities in the same cohort of patients remains to be seen. Given the association between 5-HT1a abnormalities and depression (<xref ref-type="bibr" rid="R76">Wang et al., 2016</xref>), this may reflect the common co-occurrence of depressive symptoms in people with PDP. While the degeneration of dopaminergic neurons in the substantia nigra is the hallmark of PD pathology, it is also followed by degeneration of serotonergic neurons in subcortical areas such as the raphe nuclei (<xref ref-type="bibr" rid="R71">Stahl, 2016b</xref>). Further, upregulation of 5-HT2a receptors has been observed in visual and temporal regions in PDP patients which may be a result of Lewy bodies accumulation in subcortical regions which also was associated with presence of hallucinatory behaviour (<xref ref-type="bibr" rid="R11">Birkmayer et al., 1974</xref>; <xref ref-type="bibr" rid="R34">Huot, 2018</xref>; <xref ref-type="bibr" rid="R35">Huot et al., 2010</xref>). Our results are in line with those from Vignando et al.’s (<xref ref-type="bibr" rid="R75">Vignando et al., 2021</xref>) analysis showing association between structural measures and 5-HT2a and 5-HT1a binding but not in terms of relationship with regional D1 density.</p><p id="P20">Presumably, the development of psychosis in PD patients could then be due to dysfunction in networks involved in attention control and visual information processing (<xref ref-type="bibr" rid="R40">Lenka et al., 2015</xref>; <xref ref-type="bibr" rid="R49">Muller et al., 2014</xref>; Shine, Halliday, et al., 2014; <xref ref-type="bibr" rid="R66">Shine et al., 2011</xref>; Shine, O’Callaghan, et al., 2014) that become pathological due to grey matter reduction in their nodes, as shown in the meta-analysis results, which consequently leads to abnormal functionality at a network level. Our results are to some extent different from those of the mega-analysis (<xref ref-type="bibr" rid="R75">Vignando et al., 2021</xref>) and may be due to the diverse methodologies used (mega-analysis vs. meta-analysis), the qualitative synthesis of multi-modal neuroimaging studies, the parameters used to assess atrophy (cortical thickness and surface area vs. voxel-based grey matter), and the availability of raw data (subject-level data vs. peak coordinates and one T map). They reported reduced surface area and extensive reduction in cortical thickness in occipital, temporal, parietal, frontal and limbic regions in PDP patients with visual hallucinations, identifying asymmetry in the left ventral visual pathway and extensive cortical thinning in bilateral cuneus, left dorso-medial superior frontal gyrus. Conversely, we mainly reported parietal-temporo-occipital regions as areas of significant grey matter loss and two frontal regions were found involved in PDP (the latter observed in the main analysis and in the analysis adjusted for cognitive state), our results however did not survive familywise error correction. Interestingly, we identified the right precuneus (extending to the left precuneus) as the largest cluster affected by grey matter loss in PDP patients across the three analyses (i.e., unadjusted, adjusted for PD medication and for cognition). The cuneus and precuneus were also reported as two of the areas with the greatest effect size in the principal component analysis by <xref ref-type="bibr" rid="R75">Vignando et al. (2021)</xref> examining the nodes that contributed the most to cortical thickness reduction in PDP patients, as well as in their network analysis. We conducted a whole-brain association between grey matter loss in PDP patients and receptor density examining dopaminergic and serotonergic receptors. We did not observe any relationships between grey matter volume and regional D1 density. This is in contrast with <xref ref-type="bibr" rid="R75">Vignando et al. (2021)</xref> who found associations with dopaminergic receptor density with cortical thickness in regions where PDP and PDnP had significant differences, and with surface area for significant regions of difference as well as across the cortex. However, we were only able to extract data on D1/D2 receptors unlike <xref ref-type="bibr" rid="R75">Vignando et al. (2021)</xref> who investigated the relationship with D2/D3 joint receptor density distribution. This discrepancy may also be due to methodological differences: they used mean thickness differences as the outcome variable, whilst we employed Hedges’ <italic>g</italic> effect-size estimates extracted from SDM-PSI used as a measure of grey matter loss in PDP patients, lastly they examined in-vivo PET data from an independent healthy cohort whilst we relied on gene expression data extracted from six healthy donors of the Allen Human Brain Atlas (<xref ref-type="bibr" rid="R6">Arnatkevičiūtė et al., 2019</xref>; <xref ref-type="bibr" rid="R17">Desikan et al., 2006</xref>).</p><sec id="S17"><label>4.1</label><title>Strength and limitations</title><p id="P21">The main limitations were the lack of significant results in the family-wise error corrected analyses potentially due to the small number studies and the limited access to raw imaging data as we mainly relied on peak coordinates, a less powerful approach (<xref ref-type="bibr" rid="R62">Salimi-Khorshidi et al., 2009</xref>), and that we have fewer studies than recommended guidelines (<xref ref-type="bibr" rid="R50">Müller et al., 2018</xref>). We were also unable to relate meta-analytic estimates with psychotic symptoms. These studies focused on visual hallucinations in PD. This may also be due to the different rating scales applied to assess the presence of these symptoms, some measures may not differentiate or may not be sensitive to these symptoms. Whilst some studies referred to the NINDS-NIMH criteria (<xref ref-type="bibr" rid="R57">Ravina et al., 2007</xref>), most used different assessment tools or interviews. Although visual hallucinations and illusions are the most prevalent psychotic manifestations in PD, there is evidence of patients experiencing auditory and multimodal (e.g., olfactory, tactile (<xref ref-type="bibr" rid="R16">Chou et al., 2005</xref>; <xref ref-type="bibr" rid="R69">Solla et al., 2021</xref>)) hallucinations and delusions (<xref ref-type="bibr" rid="R25">Goetz et al., 2006</xref>; <xref ref-type="bibr" rid="R44">Marsh et al., 2004</xref>; <xref ref-type="bibr" rid="R54">Papapetropoulos et al., 2008</xref>) as the disease progresses, leading to increased distress and worsening of quality of life for the patients. Future exploration should compare the neuroanatomical correlates of different psychotic symptoms in PD, as this can shed light on whether there are common pathways shared with visual hallucinations, as those observed in this meta-analysis, or symptom-specific dysfunction. A further limitation is that we used mRNA expression, a result of transcriptional and translation activity, as a measure of dopaminergic (i.e., D1, D2) and serotonergic (i.e., 5-HT2a, 5-HT1a) gene expression extracted from 6 neurotypical donors (<xref ref-type="bibr" rid="R31">Hawrylycz et al., 2012</xref>) which may not be presentative of the PD population and may introduce variability due to inter-individual differences. Nevertheless, several studies employing this methodology have shown the consistency of the receptor spatial architecture in the cortex across individuals (<xref ref-type="bibr" rid="R10">Beliveau et al., 2017</xref>; <xref ref-type="bibr" rid="R60">Rizzo et al., 2016</xref>; <xref ref-type="bibr" rid="R61">Rizzo et al., 2014</xref>; <xref ref-type="bibr" rid="R63">Selvaggi et al., 2019</xref>; <xref ref-type="bibr" rid="R73">Veronese et al., 2016</xref>). Similar approaches have been applied by other studies assessing the relationship between estimates of brain functions (from fMRI studies) and regional gene expression data, also under pharmacological intervention (<xref ref-type="bibr" rid="R5">Anderson et al., 2020</xref>; <xref ref-type="bibr" rid="R27">Gryglewski et al., 2018</xref>; <xref ref-type="bibr" rid="R59">Richiardi et al., 2015</xref>; <xref ref-type="bibr" rid="R63">Selvaggi et al., 2019</xref>; Vértes et al.). Using mRNA expression data can pave the way in the use of different techniques, also more available to the wider community, to measure regional receptor expression in the whole brain when there is a paucity of in-vivo data.</p></sec><sec id="S18" sec-type="conclusions"><label>4.2</label><title>Conclusions</title><p id="P22">In conclusion, there was grey matter volume loss in the parietal-temporal-occipital region which persisted even after adjusting for the effects of PD medications and cognitive scores. Although it may be premature to infer definite conclusions, the above evidence suggests that anomalies in brain regions involved in processing visual stimuli, over reliance on internal processing, and potential deficits in directing attention and integrating endogenous and externally derived information may underlie psychosis in PD. These findings relate to PD patients with mainly visual hallucinations due to the predominance of this symptom in the cohorts included in these studies. Furthermore, we observed an association between regional gene expression of serotonergic receptors and regional grey matter volume.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS157280-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d94aAdEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S19"><title>Acknowledgments</title><p>None</p><sec id="S20"><title>Funding</title><p>SB, LV, DA, DF, KRC and CB are in receipt of funding from Parkinson’s UK for a clinical trial in Parkinson’s disease psychosis. SP PhD studentship is funded by Parkinson’s UK. The funding source had no involvement in this research. SB is supported by grants from the National Institute of Health Research (NIHR) Efficacy and Mechanism Evaluation scheme and Parkinson’s UK. SB has participated in advisory boards for or received honoraria as a speaker from Reckitt Benckiser, EmpowerPharm/SanteCannabis and Britannia Pharmaceuticals. All of these honoraria were received as contributions toward research support through King’s College London, and not personally. SB also has collaborated with Beckley Canopy Therapeutics/ Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson’s UK) and NIHR (BRC) funded research. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. LV has collaborated with Beckley Canopy Therapeutics/ Canopy Growth (investigator-initiated research) wherein they supplied study drug for free for charity (Parkinson’s UK) and NIHR (BRC) funded research.</p></sec></ack><fn-group><fn id="FN2" fn-type="con"><p id="P23"><bold>Authors’ contributions:</bold></p><p id="P24"><italic>Conceptualisation:</italic> Sara Pisani, Latha Velayudhan, Sagnik Bhattacharyya</p><p id="P25"><italic>Methodology:</italic> Sara Pisani, Brandon Gunasekera, Latha Velayudhan, Sagnik Bhattacharyya</p><p id="P26"><italic>Investigation:</italic> Sara Pisani, Latha Velayudhan, Sagnik Bhattacharyya</p><p id="P27"><italic>Data curation:</italic> Sara Pisani, Yining Lu</p><p id="P28"><italic>Formal analysis:</italic> Sara Pisani, Brandon Gunasekera, Yining Lu, Sagnik Bhattacharyya</p><p id="P29"><italic>Visualisation:</italic> Sarra Pisani, Sagnik Bhattacharyya</p><p id="P30"><italic>Funding acquisition</italic>: Sagnik Bhattacharyya, Latha Velayudhan, Dominic ffytche, Dag</p><p id="P31">Aarsland, Kallol Ray Chaudhuri, Clive Ballard</p><p id="P32"><italic>Writing (original draft):</italic> Sara Pisani, Sagnik Bhattacharyya, Latha Velayudhan</p><p id="P33"><italic>Writing (review &amp; editing):</italic> All authors</p><p id="P34"><italic>Supervision:</italic> Latha Velayudhan, Dominic ffytche, Sagnik Bhattacharyya</p></fn><fn id="FN3" fn-type="conflict"><p id="P35"><bold>Conflict of interest:</bold> The authors have declared that no competing interests exist.</p></fn></fn-group><ref-list><ref id="R1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Brønnick</surname><given-names>K</given-names></name><name><surname>Ehrt</surname><given-names>U</given-names></name><name><surname>De Deyn</surname><given-names>PP</given-names></name><name><surname>Tekin</surname><given-names>S</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name></person-group><article-title>Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2007</year><volume>78</volume><issue>1</issue><fpage>36</fpage><lpage>42</lpage><pub-id pub-id-type="pmcid">PMC2117797</pub-id><pub-id pub-id-type="pmid">16820421</pub-id><pub-id pub-id-type="doi">10.1136/jnnp.2005.083113</pub-id></element-citation></ref><ref id="R2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albajes-Eizagirre</surname><given-names>A</given-names></name><name><surname>Solanes</surname><given-names>A</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name></person-group><article-title>Meta-analysis of non-statistically significant unreported effects</article-title><source>Statistical Methods in Medical Research</source><year>2018</year><volume>28</volume><issue>12</issue><fpage>3741</fpage><lpage>3754</lpage><pub-id pub-id-type="pmid">30514161</pub-id></element-citation></ref><ref id="R3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albajes-Eizagirre</surname><given-names>A</given-names></name><name><surname>Solanes</surname><given-names>A</given-names></name><name><surname>Vieta</surname><given-names>E</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name></person-group><article-title>Voxel-based meta-analysis via permutation of subject images (PSI): theory and implementation for SDM</article-title><source>Neuroimage</source><year>2019</year><volume>186</volume><fpage>174</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">30389629</pub-id></element-citation></ref><ref id="R4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alzahrani</surname><given-names>H</given-names></name><name><surname>Venneri</surname><given-names>A</given-names></name></person-group><article-title>Cognitive and neuroanatomical correlates of neuropsychiatric symptoms in Parkinson’s disease: A systematic review</article-title><source>J Neurol Sci</source><year>2015</year><volume>356</volume><issue>1-2</issue><fpage>32</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">26123201</pub-id></element-citation></ref><ref id="R5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>KM</given-names></name><name><surname>Collins</surname><given-names>MA</given-names></name><name><surname>Chin</surname><given-names>R</given-names></name><name><surname>Ge</surname><given-names>T</given-names></name><name><surname>Rosenberg</surname><given-names>MD</given-names></name><name><surname>Holmes</surname><given-names>AJ</given-names></name></person-group><article-title>Transcriptional and imaging-genetic association of cortical interneurons, brain function, and schizophrenia risk</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><elocation-id>2889</elocation-id><pub-id pub-id-type="pmcid">PMC7280213</pub-id><pub-id pub-id-type="pmid">32514083</pub-id><pub-id pub-id-type="doi">10.1038/s41467-020-16710-x</pub-id></element-citation></ref><ref id="R6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnatkeviĕiūtė</surname><given-names>A</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name></person-group><article-title>A practical guide to linking brain-wide gene expression and neuroimaging data</article-title><source>Neuroimage</source><year>2019</year><volume>189</volume><fpage>353</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">30648605</pub-id></element-citation></ref><ref id="R7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>MJ</given-names></name><name><surname>Blair</surname><given-names>JC</given-names></name><name><surname>Sperling</surname><given-names>SA</given-names></name><name><surname>Smolkin</surname><given-names>ME</given-names></name><name><surname>Druzgal</surname><given-names>TJ</given-names></name></person-group><article-title>Baseline symptoms and basal forebrain volume predict future psychosis in early Parkinson disease</article-title><source>Neurology</source><year>2018</year><volume>90</volume><issue>18</issue><elocation-id>e1618-e1626</elocation-id><pub-id pub-id-type="pmid">29618627</pub-id></element-citation></ref><ref id="R8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bejr-Kasem</surname><given-names>H</given-names></name><name><surname>Pagonabarraga</surname><given-names>J</given-names></name><name><surname>Martinez-Horta</surname><given-names>S</given-names></name><name><surname>Sampedro</surname><given-names>F</given-names></name><name><surname>Marin-Lahoz</surname><given-names>J</given-names></name><name><surname>Horta-Barba</surname><given-names>A</given-names></name><name><surname>Aracil-Bolanos</surname><given-names>I</given-names></name><name><surname>Perez-Perez</surname><given-names>J</given-names></name><name><surname>Boti</surname><given-names>MA</given-names></name><name><surname>Campolongo</surname><given-names>A</given-names></name><name><surname>Izquierdo</surname><given-names>C</given-names></name><etal/></person-group><article-title>Disruption of the default mode network and its intrinsic functional connectivity underlies minor hallucinations in Parkinson’s disease [Article]</article-title><source>Movement Disorders</source><year>2019</year><volume>34</volume><issue>1</issue><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">30536829</pub-id></element-citation></ref><ref id="R9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bejr-Kasem</surname><given-names>H</given-names></name><name><surname>Sampedro</surname><given-names>F</given-names></name><name><surname>Marín-Lahoz</surname><given-names>J</given-names></name><name><surname>Martínez-Horta</surname><given-names>S</given-names></name><name><surname>Pagonabarraga</surname><given-names>J</given-names></name><name><surname>Kulisevsky</surname><given-names>J</given-names></name></person-group><article-title>Minor hallucinations reflect early gray matter loss and predict subjective cognitive decline in parkinson’s disease</article-title><source>Eur J Neurol</source><year>2020</year><pub-id pub-id-type="pmid">33032389</pub-id></element-citation></ref><ref id="R10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beliveau</surname><given-names>V</given-names></name><name><surname>Ganz</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>L</given-names></name><name><surname>Ozenne</surname><given-names>B</given-names></name><name><surname>Højgaard</surname><given-names>L</given-names></name><name><surname>Fisher</surname><given-names>PM</given-names></name><name><surname>Svarer</surname><given-names>C</given-names></name><name><surname>Greve</surname><given-names>DN</given-names></name><name><surname>Knudsen</surname><given-names>GM</given-names></name></person-group><article-title>A High-Resolution &lt;em&gt;In Vivo&lt;/em&gt; Atlas of the Human Brain’s Serotonin System</article-title><source>The Journal of Neuroscience</source><year>2017</year><volume>37</volume><issue>1</issue><fpage>120</fpage><pub-id pub-id-type="pmcid">PMC5214625</pub-id><pub-id pub-id-type="pmid">28053035</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.2830-16.2016</pub-id></element-citation></ref><ref id="R11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birkmayer</surname><given-names>W</given-names></name><name><surname>Danielczyk</surname><given-names>W</given-names></name><name><surname>Neumayer</surname><given-names>E</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name></person-group><article-title>Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings</article-title><source>J Neural Transm</source><year>1974</year><volume>35</volume><issue>2</issue><fpage>93</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">4844103</pub-id></element-citation></ref><ref id="R12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boecker</surname><given-names>H</given-names></name><name><surname>Ceballos-Baumann</surname><given-names>AO</given-names></name><name><surname>Volk</surname><given-names>D</given-names></name><name><surname>Conrad</surname><given-names>B</given-names></name><name><surname>Forstl</surname><given-names>H</given-names></name><name><surname>Haussermann</surname><given-names>P</given-names></name></person-group><article-title>Metabolic alterations in patients with Parkinson disease and visual hallucinations</article-title><source>Archives of Neurology</source><year>2007</year><volume>64</volume><issue>7</issue><fpage>984</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">17620488</pub-id></element-citation></ref><ref id="R13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Andrews-Hanna</surname><given-names>JR</given-names></name><name><surname>Schacter</surname><given-names>DL</given-names></name></person-group><article-title>The Brain’s Default Network</article-title><source>Annals of the New York Academy of Sciences</source><year>2008</year><volume>1124</volume><issue>1</issue><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">18400922</pub-id></element-citation></ref><ref id="R14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavanna</surname><given-names>AE</given-names></name><name><surname>Trimble</surname><given-names>MR</given-names></name></person-group><article-title>The precuneus: a review of its functional anatomy and behavioural correlates</article-title><source>Brain</source><year>2006</year><volume>129</volume><issue>3</issue><fpage>564</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">16399806</pub-id></element-citation></ref><ref id="R15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>SH</given-names></name></person-group><article-title>Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management</article-title><source>Drugs</source><year>2016</year><volume>76</volume><issue>11</issue><fpage>1093</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">27312429</pub-id></element-citation></ref><ref id="R16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>KL</given-names></name><name><surname>Messing</surname><given-names>S</given-names></name><name><surname>Oakes</surname><given-names>D</given-names></name><name><surname>Feldman</surname><given-names>PD</given-names></name><name><surname>Breier</surname><given-names>A</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><article-title>Drug-induced psychosis in Parkinson disease - Phenomenology and correlations among psychosis rating instruments</article-title><source>Clinical Neuropharmacology</source><year>2005</year><volume>28</volume><issue>5</issue><fpage>215</fpage><lpage>219</lpage><comment>[Article; Proceedings Paper]</comment><pub-id pub-id-type="pmid">16239760</pub-id></element-citation></ref><ref id="R17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desikan</surname><given-names>RS</given-names></name><name><surname>Ségonne</surname><given-names>F</given-names></name><name><surname>Fischl</surname><given-names>B</given-names></name><name><surname>Quinn</surname><given-names>BT</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Maguire</surname><given-names>RP</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>Killiany</surname><given-names>RJ</given-names></name></person-group><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>Neuroimage</source><year>2006</year><volume>31</volume><issue>3</issue><fpage>968</fpage><lpage>980</lpage><pub-id pub-id-type="pmid">16530430</pub-id></element-citation></ref><ref id="R18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group><article-title>Bias in meta-analysis detected by a simple, graphical test</article-title><source>Bmj</source><year>1997</year><volume>315</volume><issue>7109</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmcid">PMC2127453</pub-id><pub-id pub-id-type="pmid">9310563</pub-id><pub-id pub-id-type="doi">10.1136/bmj.315.7109.629</pub-id></element-citation></ref><ref id="R19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Factor</surname><given-names>SA</given-names></name><name><surname>Scullin</surname><given-names>MK</given-names></name><name><surname>Sollinger</surname><given-names>AB</given-names></name><name><surname>Land</surname><given-names>JO</given-names></name><name><surname>Wood-Siverio</surname><given-names>C</given-names></name><name><surname>Zanders</surname><given-names>L</given-names></name><name><surname>Freeman</surname><given-names>A</given-names></name><name><surname>Bliwise</surname><given-names>DL</given-names></name><name><surname>McDonald</surname><given-names>WM</given-names></name><name><surname>Goldstein</surname><given-names>FC</given-names></name></person-group><article-title>Cognitive correlates of hallucinations and delusions in Parkinson’s disease</article-title><source>J Neurol Sci</source><year>2014</year><volume>347</volume><issue>1-2</issue><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">25466695</pub-id></element-citation></ref><ref id="R20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ffytche</surname><given-names>DH</given-names></name><name><surname>Creese</surname><given-names>B</given-names></name><name><surname>Politis</surname><given-names>M</given-names></name><name><surname>Chaudhuri</surname><given-names>KR</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name></person-group><article-title>The psychosis spectrum in Parkinson disease</article-title><source>Nat Rev Neurol</source><year>2017</year><volume>13</volume><issue>2</issue><fpage>81</fpage><lpage>95</lpage><pub-id pub-id-type="pmcid">PMC5656278</pub-id><pub-id pub-id-type="pmid">28106066</pub-id><pub-id pub-id-type="doi">10.1038/nrneurol.2016.200</pub-id></element-citation></ref><ref id="R21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firbank</surname><given-names>MJ</given-names></name><name><surname>Parikh</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>N</given-names></name><name><surname>Killen</surname><given-names>A</given-names></name><name><surname>Allan</surname><given-names>CL</given-names></name><name><surname>Collerton</surname><given-names>D</given-names></name><name><surname>Blamire</surname><given-names>AM</given-names></name><name><surname>Taylor</surname><given-names>J-P</given-names></name></person-group><article-title>Reduced occipital GABA in Parkinson disease with visual hallucinations</article-title><source>Neurology</source><year>2018</year><volume>91</volume><issue>7</issue><elocation-id>e675</elocation-id><pub-id pub-id-type="pmcid">PMC6105043</pub-id><pub-id pub-id-type="pmid">30021920</pub-id><pub-id pub-id-type="doi">10.1212/WNL.0000000000006007</pub-id></element-citation></ref><ref id="R22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freton</surname><given-names>M</given-names></name><name><surname>Lemogne</surname><given-names>C</given-names></name><name><surname>Bergouignan</surname><given-names>L</given-names></name><name><surname>Delaveau</surname><given-names>P</given-names></name><name><surname>Lehéricy</surname><given-names>S</given-names></name><name><surname>Fossati</surname><given-names>P</given-names></name></person-group><article-title>The eye of the self: precuneus volume and visual perspective during autobiographical memory retrieval</article-title><source>Brain Structure and Function</source><year>2014</year><volume>219</volume><issue>3</issue><fpage>959</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">23553546</pub-id></element-citation></ref><ref id="R23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><article-title>Minor hallucinations occur in drug-naive Parkinson’s disease patients even from the premotor phase</article-title><source>Movement Disorders</source><year>2016</year><volume>31</volume><issue>3</issue><fpage>433</fpage><comment>(vol 31, pg 9, 2016) [Correction]</comment><pub-id pub-id-type="pmid">26952120</pub-id></element-citation></ref><ref id="R24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gama</surname><given-names>RL</given-names></name><name><surname>Bruin</surname><given-names>VM</given-names></name><name><surname>Távora</surname><given-names>DG</given-names></name><name><surname>Duran</surname><given-names>FL</given-names></name><name><surname>Bittencourt</surname><given-names>L</given-names></name><name><surname>Tufik</surname><given-names>S</given-names></name></person-group><article-title>Structural brain abnormalities in patients with Parkinson’s disease with visual hallucinations: a comparative voxel-based analysis</article-title><source>Brain Cogn</source><year>2014</year><volume>87</volume><fpage>97</fpage><lpage>103</lpage><pub-id pub-id-type="pmid">24732953</pub-id></element-citation></ref><ref id="R25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Wuu</surname><given-names>J</given-names></name><name><surname>Curgian</surname><given-names>L</given-names></name><name><surname>Leurgans</surname><given-names>S</given-names></name></person-group><article-title>Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson’s disease patients</article-title><source>Movement Disorders</source><year>2006</year><volume>21</volume><issue>2</issue><fpage>267</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">16161144</pub-id></element-citation></ref><ref id="R26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>JG</given-names></name><name><surname>Stebbins</surname><given-names>GT</given-names></name><name><surname>Dinh</surname><given-names>V</given-names></name><name><surname>Bernard</surname><given-names>B</given-names></name><name><surname>Merkitch</surname><given-names>D</given-names></name><name><surname>deToledo-Morrell</surname><given-names>L</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name></person-group><article-title>Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations</article-title><source>Brain</source><year>2014</year><volume>137</volume><issue>3</issue><fpage>849</fpage><lpage>859</lpage><pub-id pub-id-type="pmcid">PMC3983409</pub-id><pub-id pub-id-type="pmid">24480486</pub-id><pub-id pub-id-type="doi">10.1093/brain/awt360</pub-id></element-citation></ref><ref id="R27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryglewski</surname><given-names>G</given-names></name><name><surname>Seiger</surname><given-names>R</given-names></name><name><surname>James</surname><given-names>GM</given-names></name><name><surname>Godbersen</surname><given-names>GM</given-names></name><name><surname>Komorowski</surname><given-names>A</given-names></name><name><surname>Unterholzner</surname><given-names>J</given-names></name><name><surname>Michenthaler</surname><given-names>P</given-names></name><name><surname>Hahn</surname><given-names>A</given-names></name><name><surname>Wadsak</surname><given-names>W</given-names></name><name><surname>Mitterhauser</surname><given-names>M</given-names></name><name><surname>Kasper</surname><given-names>S</given-names></name><etal/></person-group><article-title>Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging</article-title><source>Neuroimage</source><year>2018</year><volume>176</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">29723639</pub-id></element-citation></ref><ref id="R28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hacksell</surname><given-names>U</given-names></name><name><surname>Burstein</surname><given-names>ES</given-names></name><name><surname>McFarland</surname><given-names>K</given-names></name><name><surname>Mills</surname><given-names>RG</given-names></name><name><surname>Williams</surname><given-names>H</given-names></name></person-group><article-title>On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis</article-title><source>Neurochemical research</source><year>2014</year><volume>39</volume><issue>10</issue><fpage>2008</fpage><lpage>2017</lpage><pub-id pub-id-type="pmcid">PMC4172996</pub-id><pub-id pub-id-type="pmid">24682754</pub-id><pub-id pub-id-type="doi">10.1007/s11064-014-1293-3</pub-id></element-citation></ref><ref id="R29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafkemeijer</surname><given-names>A</given-names></name><name><surname>van der Grond</surname><given-names>J</given-names></name><name><surname>Rombouts</surname><given-names>SARB</given-names></name></person-group><article-title>Imaging the default mode network in aging and dementia</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</source><year>2012</year><volume>1822</volume><issue>3</issue><fpage>431</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">21807094</pub-id></element-citation></ref><ref id="R30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>JM</given-names></name><name><surname>O’Callaghan</surname><given-names>C</given-names></name><name><surname>Muller</surname><given-names>AJ</given-names></name><name><surname>Martens</surname><given-names>KAE</given-names></name><name><surname>Phillips</surname><given-names>JR</given-names></name><name><surname>Moustafa</surname><given-names>AA</given-names></name><name><surname>Lewis</surname><given-names>SJG</given-names></name><name><surname>Shine</surname><given-names>JM</given-names></name></person-group><article-title>Changes in structural network topology correlate with severity of hallucinatory behavior in Parkinson’s disease [Article]</article-title><source>Network Neuroscience</source><year>2019</year><volume>3</volume><issue>2</issue><fpage>521</fpage><lpage>538</lpage><pub-id pub-id-type="pmcid">PMC6444885</pub-id><pub-id pub-id-type="pmid">30984905</pub-id><pub-id pub-id-type="doi">10.1162/netn_a_00078</pub-id></element-citation></ref><ref id="R31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawrylycz</surname><given-names>MJ</given-names></name><name><surname>Lein</surname><given-names>ES</given-names></name><name><surname>Guillozet-Bongaarts</surname><given-names>AL</given-names></name><name><surname>Shen</surname><given-names>EH</given-names></name><name><surname>Ng</surname><given-names>L</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>van de Lagemaat</surname><given-names>LN</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Ebbert</surname><given-names>A</given-names></name><name><surname>Riley</surname><given-names>ZL</given-names></name><name><surname>Abajian</surname><given-names>C</given-names></name><etal/></person-group><article-title>An anatomically comprehensive atlas of the adult human brain transcriptome</article-title><source>Nature</source><year>2012</year><volume>489</volume><issue>7416</issue><fpage>391</fpage><lpage>399</lpage><pub-id pub-id-type="pmcid">PMC4243026</pub-id><pub-id pub-id-type="pmid">22996553</pub-id><pub-id pub-id-type="doi">10.1038/nature11405</pub-id></element-citation></ref><ref id="R32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hepp</surname><given-names>DH</given-names></name><name><surname>Foncke</surname><given-names>EMJ</given-names></name><name><surname>Berendse</surname><given-names>HW</given-names></name><name><surname>Wassenaar</surname><given-names>TM</given-names></name><name><surname>Dubbelink</surname><given-names>K</given-names></name><name><surname>Groenewegen</surname><given-names>HJ</given-names></name><name><surname>van de Berg</surname><given-names>WDJ</given-names></name><name><surname>Schoonheim</surname><given-names>MM</given-names></name></person-group><article-title>Damaged fiber tracts of the nucleus basalis of Meynert in Parkinson’s disease patients with visual hallucinations [Article]</article-title><source>Scientific Reports</source><year>2017</year><volume>7</volume><pub-id pub-id-type="pmcid">PMC5579278</pub-id><pub-id pub-id-type="pmid">28860465</pub-id><pub-id pub-id-type="doi">10.1038/s41598-017-10146-y</pub-id></element-citation></ref><ref id="R33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Measuring inconsistency in meta-analyses</article-title><source>Bmj</source><year>2003</year><volume>327</volume><issue>7414</issue><fpage>557</fpage><lpage>560</lpage><pub-id pub-id-type="pmcid">PMC192859</pub-id><pub-id pub-id-type="pmid">12958120</pub-id><pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id></element-citation></ref><ref id="R34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huot</surname><given-names>P</given-names></name></person-group><article-title>5-HT(2A) receptors and Parkinson’s disease psychosis: a pharmacological discussion</article-title><source>Neurodegener Dis Manag</source><year>2018</year><volume>8</volume><issue>6</issue><fpage>363</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">30451579</pub-id></element-citation></ref><ref id="R35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huot</surname><given-names>P</given-names></name><name><surname>Johnston</surname><given-names>TH</given-names></name><name><surname>Darr</surname><given-names>T</given-names></name><name><surname>Hazrati</surname><given-names>LN</given-names></name><name><surname>Visanji</surname><given-names>NP</given-names></name><name><surname>Pires</surname><given-names>D</given-names></name><name><surname>Brotchie</surname><given-names>JM</given-names></name><name><surname>Fox</surname><given-names>SH</given-names></name></person-group><article-title>Increased 5-HT&lt;inf&gt;2A&lt;/inf&gt; receptors in the temporal cortex of Parkinsonian patients with visual hallucinations</article-title><source>Movement Disorders</source><year>2010</year><volume>25</volume><issue>10</issue><fpage>1399</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">20629135</pub-id></element-citation></ref><ref id="R36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>P</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name></person-group><article-title>Precuneus dysfunction in Parkinson’s disease with mild cognitive impairment</article-title><source>Frontiers in aging neuroscience</source><year>2019</year><volume>10</volume><fpage>427</fpage><pub-id pub-id-type="pmcid">PMC6338059</pub-id><pub-id pub-id-type="pmid">30687078</pub-id><pub-id pub-id-type="doi">10.3389/fnagi.2018.00427</pub-id></element-citation></ref><ref id="R37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawn</surname><given-names>T</given-names></name></person-group><article-title>Cerebellar correlates of visual hallucinations in Parkinson’s disease and Charles Bonnet Syndrome</article-title><source>Cortex</source><year>2021</year><volume>135</volume><fpage>311</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">33390262</pub-id></element-citation></ref><ref id="R38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>WW</given-names></name><name><surname>Yoon</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name></person-group><article-title>Visual Hallucination and Pattern of Brain Degeneration in Parkinsons Disease [Article]</article-title><source>Neurodegenerative Diseases</source><year>2017</year><volume>17</volume><issue>2-3</issue><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">27760431</pub-id></element-citation></ref><ref id="R39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>S</given-names></name><name><surname>Baille</surname><given-names>G</given-names></name><name><surname>Jardri</surname><given-names>R</given-names></name><name><surname>Plomhause</surname><given-names>L</given-names></name><name><surname>Szaffarczyk</surname><given-names>S</given-names></name><name><surname>Defebvre</surname><given-names>L</given-names></name><name><surname>Thomas</surname><given-names>P</given-names></name><name><surname>Delmaire</surname><given-names>C</given-names></name><name><surname>Pins</surname><given-names>D</given-names></name><name><surname>Dujardin</surname><given-names>K</given-names></name></person-group><article-title>Hallucinations and conscious access to visual inputs in Parkinson’s disease</article-title><source>Scientific Reports</source><year>2016</year><volume>6</volume><issue>1</issue><elocation-id>36284</elocation-id><pub-id pub-id-type="pmcid">PMC5107911</pub-id><pub-id pub-id-type="pmid">27841268</pub-id><pub-id pub-id-type="doi">10.1038/srep36284</pub-id></element-citation></ref><ref id="R40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenka</surname><given-names>A</given-names></name><name><surname>Jhunjhunwala</surname><given-names>KR</given-names></name><name><surname>Saini</surname><given-names>J</given-names></name><name><surname>Pal</surname><given-names>PK</given-names></name></person-group><article-title>Structural and functional neuroimaging in patients with Parkinson’s disease and visual hallucinations: A critical review</article-title><source>Parkinsonism Relat Disord</source><year>2015</year><volume>21</volume><issue>7</issue><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">25920541</pub-id></element-citation></ref><ref id="R41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Wan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>T</given-names></name></person-group><article-title>Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range</article-title><source>Stat Methods Med Res</source><year>2018</year><volume>27</volume><issue>6</issue><fpage>1785</fpage><lpage>1805</lpage><pub-id pub-id-type="pmid">27683581</pub-id></element-citation></ref><ref id="R42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majlath</surname><given-names>Z</given-names></name><name><surname>Obal</surname><given-names>I</given-names></name><name><surname>Vecsei</surname><given-names>L</given-names></name></person-group><article-title>Treatment Possibilities for Psychosis in Parkinson’s Disease with An Emphasis on the Newly Approved Drug: Pimavanserin</article-title><source>CNS Neurol Disord Drug Targets</source><year>2017</year><volume>16</volume><issue>3</issue><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">27719624</pub-id></element-citation></ref><ref id="R43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markello</surname><given-names>RD</given-names></name><name><surname>Arnatkeviciute</surname><given-names>A</given-names></name><name><surname>Poline</surname><given-names>JB</given-names></name><name><surname>Fulcher</surname><given-names>BD</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Misic</surname><given-names>B</given-names></name></person-group><article-title>Standardizing workflows in imaging transcriptomics with the abagen toolbox</article-title><source>Elife</source><year>2021</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC8660024</pub-id><pub-id pub-id-type="pmid">34783653</pub-id><pub-id pub-id-type="doi">10.7554/eLife.72129</pub-id></element-citation></ref><ref id="R44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>JR</given-names></name><name><surname>Rocco</surname><given-names>M</given-names></name><name><surname>Grill</surname><given-names>S</given-names></name><name><surname>Munro</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name></person-group><article-title>Psychiatric comorbidities in patients with Parkinson disease and psychosis</article-title><source>Neurology</source><year>2004</year><volume>63</volume><issue>2</issue><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">15277623</pub-id></element-citation></ref><ref id="R45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Martin</surname><given-names>P</given-names></name><name><surname>Rodriguez-Blazquez</surname><given-names>C</given-names></name><name><surname>Forjaz</surname><given-names>MJ</given-names></name><name><surname>Frades-Payo</surname><given-names>B</given-names></name><name><surname>Agüera-Ortiz</surname><given-names>L</given-names></name><name><surname>Weintraub</surname><given-names>D</given-names></name><name><surname>Riesco</surname><given-names>A</given-names></name><name><surname>Kurtis</surname><given-names>MM</given-names></name><name><surname>Chaudhuri</surname><given-names>KR</given-names></name></person-group><article-title>Neuropsychiatric symptoms and caregiver’s burden in Parkinson’s disease</article-title><source>Parkinsonism Relat Disord</source><year>2015</year><volume>21</volume><issue>6</issue><fpage>629</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">25892660</pub-id></element-citation></ref><ref id="R46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meltzer</surname><given-names>HY</given-names></name><name><surname>Mills</surname><given-names>R</given-names></name><name><surname>Revell</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Bahr</surname><given-names>D</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group><article-title>Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis</article-title><source>Neuropsychopharmacology</source><year>2010</year><volume>35</volume><issue>4</issue><fpage>881</fpage><lpage>892</lpage><pub-id pub-id-type="pmcid">PMC3055369</pub-id><pub-id pub-id-type="pmid">19907417</pub-id><pub-id pub-id-type="doi">10.1038/npp.2009.176</pub-id></element-citation></ref><ref id="R47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanty</surname><given-names>D</given-names></name><name><surname>Sarai</surname><given-names>S</given-names></name><name><surname>Naik</surname><given-names>S</given-names></name><name><surname>Lippmann</surname><given-names>S</given-names></name></person-group><article-title>Pimavanserin for Parkinson Disease Psychosis</article-title><source>Prim Care Companion CNS Disord</source><year>2019</year><volume>21</volume><issue>2</issue><pub-id pub-id-type="pmid">31050230</pub-id></element-citation></ref><ref id="R48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Liberati</surname><given-names>A</given-names></name><name><surname>Tetzlaff</surname><given-names>J</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>The</surname><given-names>PG</given-names></name></person-group><article-title>Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement</article-title><source>PLOS Medicine</source><year>2009</year><volume>6</volume><issue>7</issue><elocation-id>e1000097</elocation-id><pub-id pub-id-type="pmcid">PMC2707599</pub-id><pub-id pub-id-type="pmid">19621072</pub-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1000097</pub-id></element-citation></ref><ref id="R49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>AJ</given-names></name><name><surname>Shine</surname><given-names>JM</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Lewis</surname><given-names>SJ</given-names></name></person-group><article-title>Visual hallucinations in Parkinson’s disease: theoretical models</article-title><source>Movement Disorders</source><year>2014</year><volume>29</volume><issue>13</issue><fpage>1591</fpage><lpage>1598</lpage><pub-id pub-id-type="pmid">25154807</pub-id></element-citation></ref><ref id="R50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>VI</given-names></name><name><surname>Cieslik</surname><given-names>EC</given-names></name><name><surname>Laird</surname><given-names>AR</given-names></name><name><surname>Fox</surname><given-names>PT</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name><name><surname>Mataix-Cols</surname><given-names>D</given-names></name><name><surname>Tench</surname><given-names>CR</given-names></name><name><surname>Yarkoni</surname><given-names>T</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name><name><surname>Turkeltaub</surname><given-names>PE</given-names></name><name><surname>Wager</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Ten simple rules for neuroimaging meta-analysis</article-title><source>Neuroscience &amp; Biobehavioral Reviews</source><year>2018</year><volume>84</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="pmcid">PMC5918306</pub-id><pub-id pub-id-type="pmid">29180258</pub-id><pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.11.012</pub-id></element-citation></ref><ref id="R51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishio</surname><given-names>Y</given-names></name><name><surname>Yokoi</surname><given-names>K</given-names></name><name><surname>Hirayama</surname><given-names>K</given-names></name><name><surname>Ishioka</surname><given-names>T</given-names></name><name><surname>Hosokai</surname><given-names>Y</given-names></name><name><surname>Gang</surname><given-names>M</given-names></name><name><surname>Uschiyama</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Mori</surname><given-names>E</given-names></name></person-group><article-title>Defining visual illusions in Parkinson’s disease: Kinetopsia and object misidentification illusions</article-title><source>Parkinsonism &amp; related disorders</source><year>2018</year><volume>55</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">29891431</pub-id></element-citation></ref><ref id="R52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagonabarraga</surname><given-names>J</given-names></name><name><surname>Martinez-Horta</surname><given-names>S</given-names></name><name><surname>Fernández de Bobadilla</surname><given-names>R</given-names></name><name><surname>Pérez</surname><given-names>J</given-names></name><name><surname>Ribosa-Nogué</surname><given-names>R</given-names></name><name><surname>Marín</surname><given-names>J</given-names></name><name><surname>Pascual-Sedano</surname><given-names>B</given-names></name><name><surname>García</surname><given-names>C</given-names></name><name><surname>Gironell</surname><given-names>A</given-names></name><name><surname>Kulisevsky</surname><given-names>J</given-names></name></person-group><article-title>Minor hallucinations occur in drug-naive Parkinson’s disease patients, even from the premotor phase</article-title><source>Mov Disord</source><year>2016</year><volume>31</volume><issue>1</issue><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">26408291</pub-id></element-citation></ref><ref id="R53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagonabarraga</surname><given-names>J</given-names></name><name><surname>Soriano-Mas</surname><given-names>C</given-names></name><name><surname>Llebaria</surname><given-names>G</given-names></name><name><surname>López-Solà</surname><given-names>M</given-names></name><name><surname>Pujol</surname><given-names>J</given-names></name><name><surname>Kulisevsky</surname><given-names>J</given-names></name></person-group><article-title>Neural correlates of minor hallucinations in non-demented patients with Parkinson’s disease</article-title><source>Parkinsonism &amp; Related Disorders</source><year>2014</year><volume>20</volume><issue>3</issue><fpage>290</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">24373690</pub-id></element-citation></ref><ref id="R54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papapetropoulos</surname><given-names>S</given-names></name><name><surname>Katzen</surname><given-names>H</given-names></name><name><surname>Schrag</surname><given-names>A</given-names></name><name><surname>Singer</surname><given-names>C</given-names></name><name><surname>Scanlon</surname><given-names>BK</given-names></name><name><surname>Nation</surname><given-names>D</given-names></name><name><surname>Guevara</surname><given-names>A</given-names></name><name><surname>Levin</surname><given-names>B</given-names></name></person-group><article-title>A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease</article-title><source>BMC neurology</source><year>2008</year><volume>8</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC2443167</pub-id><pub-id pub-id-type="pmid">18570642</pub-id><pub-id pub-id-type="doi">10.1186/1471-2377-8-21</pub-id></element-citation></ref><ref id="R55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pezzoli</surname><given-names>S</given-names></name><name><surname>Sánchez-Valle</surname><given-names>R</given-names></name><name><surname>Solanes</surname><given-names>A</given-names></name><name><surname>Kempton</surname><given-names>MJ</given-names></name><name><surname>Bandmann</surname><given-names>O</given-names></name><name><surname>Shin</surname><given-names>JI</given-names></name><name><surname>Cagnin</surname><given-names>A</given-names></name><name><surname>Goldman</surname><given-names>JG</given-names></name><name><surname>Merkitch</surname><given-names>D</given-names></name><name><surname>Firbank</surname><given-names>MJ</given-names></name></person-group><article-title>Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson’s disease and dementia with Lewy bodies: voxel-based morphometry and neuropsychological meta-analysis</article-title><source>Neuroscience &amp; Biobehavioral Reviews</source><year>2021</year><volume>128</volume><fpage>367</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">34171324</pub-id></element-citation></ref><ref id="R56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramírez-Ruiz</surname><given-names>B</given-names></name><name><surname>Martí</surname><given-names>MJ</given-names></name><name><surname>Tolosa</surname><given-names>E</given-names></name><name><surname>Gimenez</surname><given-names>M</given-names></name><name><surname>Bargallo</surname><given-names>N</given-names></name><name><surname>Valldeoriola</surname><given-names>F</given-names></name><name><surname>Junque</surname><given-names>C</given-names></name></person-group><article-title>Cerebral atrophy in Parkinson’s disease patients with visual hallucinations</article-title><source>European Journal of Neurology</source><year>2007</year><volume>14</volume><issue>7</issue><fpage>750</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">17594330</pub-id></element-citation></ref><ref id="R57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravina</surname><given-names>B</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Fernandez</surname><given-names>HH</given-names></name><name><surname>Friedman</surname><given-names>JH</given-names></name><name><surname>McDonald</surname><given-names>W</given-names></name><name><surname>Murphy</surname><given-names>D</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Babcock</surname><given-names>D</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Endicott</surname><given-names>J</given-names></name></person-group><article-title>Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group</article-title><source>Movement Disorders</source><year>2007</year><volume>22</volume><issue>8</issue><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">17266092</pub-id></element-citation></ref><ref id="R58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rektorova</surname><given-names>I</given-names></name><name><surname>Krajcovicova</surname><given-names>L</given-names></name><name><surname>Marecek</surname><given-names>R</given-names></name><name><surname>Novakova</surname><given-names>M</given-names></name><name><surname>Mikl</surname><given-names>M</given-names></name></person-group><article-title>Default Mode Network Connectivity Patterns associated with Visual Processing at Different Stages of Parkinson’s Disease</article-title><source>Journal of Alzheimers Disease</source><year>2014</year><volume>42</volume><fpage>S217</fpage><lpage>S228</lpage><pub-id pub-id-type="pmid">25114077</pub-id></element-citation></ref><ref id="R59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richiardi</surname><given-names>J</given-names></name><name><surname>Altmann</surname><given-names>A</given-names></name><name><surname>Milazzo</surname><given-names>A-C</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Chakravarty</surname><given-names>MM</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Barker</surname><given-names>GJ</given-names></name><name><surname>Bokde</surname><given-names>ALW</given-names></name><name><surname>Bromberg</surname><given-names>U</given-names></name><name><surname>Büchel</surname><given-names>C</given-names></name><name><surname>Conrod</surname><given-names>P</given-names></name><etal/></person-group><article-title>Correlated gene expression supports synchronous activity in brain networks</article-title><source>Science</source><year>2015</year><volume>348</volume><issue>6240</issue><fpage>1241</fpage><lpage>1244</lpage><pub-id pub-id-type="pmcid">PMC4829082</pub-id><pub-id pub-id-type="pmid">26068849</pub-id><pub-id pub-id-type="doi">10.1126/science.1255905</pub-id></element-citation></ref><ref id="R60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Veronese</surname><given-names>M</given-names></name><name><surname>Expert</surname><given-names>P</given-names></name><name><surname>Turkheimer</surname><given-names>FE</given-names></name><name><surname>Bertoldo</surname><given-names>A</given-names></name></person-group><article-title>MENGA: A New Comprehensive Tool for the Integration of Neuroimaging Data and the Allen Human Brain Transcriptome Atlas</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><issue>2</issue><elocation-id>e0148744</elocation-id><pub-id pub-id-type="pmcid">PMC4755531</pub-id><pub-id pub-id-type="pmid">26882227</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0148744</pub-id></element-citation></ref><ref id="R61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Veronese</surname><given-names>M</given-names></name><name><surname>Heckemann</surname><given-names>RA</given-names></name><name><surname>Selvaraj</surname><given-names>S</given-names></name><name><surname>Howes</surname><given-names>OD</given-names></name><name><surname>Hammers</surname><given-names>A</given-names></name><name><surname>Turkheimer</surname><given-names>FE</given-names></name><name><surname>Bertoldo</surname><given-names>A</given-names></name></person-group><article-title>The Predictive Power of Brain mRNA Mappings for in vivo Protein Density: A Positron Emission Tomography Correlation Study</article-title><source>Journal of Cerebral Blood Flow &amp; Metabolism</source><year>2014</year><volume>34</volume><issue>5</issue><fpage>827</fpage><lpage>835</lpage><pub-id pub-id-type="pmcid">PMC4013760</pub-id><pub-id pub-id-type="pmid">24496175</pub-id><pub-id pub-id-type="doi">10.1038/jcbfm.2014.21</pub-id></element-citation></ref><ref id="R62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salimi-Khorshidi</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Keltner</surname><given-names>JR</given-names></name><name><surname>Wager</surname><given-names>TD</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name></person-group><article-title>Meta-analysis of neuroimaging data: A comparison of image-based and coordinate-based pooling of studies</article-title><source>Neuroimage</source><year>2009</year><volume>45</volume><issue>3</issue><fpage>810</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">19166944</pub-id></element-citation></ref><ref id="R63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvaggi</surname><given-names>P</given-names></name><name><surname>Hawkins</surname><given-names>PCT</given-names></name><name><surname>Dipasquale</surname><given-names>O</given-names></name><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Bertolino</surname><given-names>A</given-names></name><name><surname>Dukart</surname><given-names>J</given-names></name><name><surname>Sambataro</surname><given-names>F</given-names></name><name><surname>Pergola</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>SCR</given-names></name><name><surname>Turkheimer</surname><given-names>F</given-names></name><name><surname>Zelaya</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles</article-title><source>Neuroimage</source><year>2019</year><volume>188</volume><fpage>774</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">30553916</pub-id></element-citation></ref><ref id="R64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Hong</surname><given-names>JY</given-names></name><name><surname>Sunwoo</surname><given-names>M-K</given-names></name><name><surname>Sohn</surname><given-names>YH</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name></person-group><article-title>Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson’s disease</article-title><source>Journal of neurology, neurosurgery &amp; psychiatry</source><year>2012</year><volume>83</volume><issue>12</issue><fpage>1155</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">22933812</pub-id></element-citation></ref><ref id="R65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shine</surname><given-names>JM</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Gilat</surname><given-names>M</given-names></name><name><surname>Matar</surname><given-names>E</given-names></name><name><surname>Bolitho</surname><given-names>SJ</given-names></name><name><surname>Carlos</surname><given-names>M</given-names></name><name><surname>Naismith</surname><given-names>SL</given-names></name><name><surname>Lewis</surname><given-names>SJ</given-names></name></person-group><article-title>The role of dysfunctional attentional control networks in visual misperceptions in Parkinson’s disease</article-title><source>Human Brain Mapping</source><year>2014</year><volume>35</volume><issue>5</issue><fpage>2206</fpage><lpage>2219</lpage><pub-id pub-id-type="pmcid">PMC6869072</pub-id><pub-id pub-id-type="pmid">23760982</pub-id><pub-id pub-id-type="doi">10.1002/hbm.22321</pub-id></element-citation></ref><ref id="R66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shine</surname><given-names>JM</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Naismith</surname><given-names>SL</given-names></name><name><surname>Lewis</surname><given-names>SJG</given-names></name></person-group><article-title>Visual Misperceptions and Hallucinations in Parkinson’s Disease: Dysfunction of Attentional Control Networks? [Article]</article-title><source>Movement Disorders</source><year>2011</year><volume>26</volume><issue>12</issue><fpage>2154</fpage><lpage>2159</lpage><pub-id pub-id-type="pmid">21953814</pub-id></element-citation></ref><ref id="R67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shine</surname><given-names>JM</given-names></name><name><surname>Keogh</surname><given-names>R</given-names></name><name><surname>O’Callaghan</surname><given-names>C</given-names></name><name><surname>Muller</surname><given-names>AJ</given-names></name><name><surname>Lewis</surname><given-names>SJG</given-names></name><name><surname>Pearson</surname><given-names>J</given-names></name></person-group><article-title>Imagine that: elevated sensory strength of mental imagery in individuals with Parkinson’s disease and visual hallucinations [Article]</article-title><source>Proceedings of the Royal Society B-Biological Sciences</source><year>2015</year><volume>282</volume><issue>1798</issue><pub-id pub-id-type="pmcid">PMC4262172</pub-id><pub-id pub-id-type="pmid">25429016</pub-id><pub-id pub-id-type="doi">10.1098/rspb.2014.2047</pub-id></element-citation></ref><ref id="R68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shine</surname><given-names>JM</given-names></name><name><surname>O’Callaghan</surname><given-names>C</given-names></name><name><surname>Halliday</surname><given-names>GM</given-names></name><name><surname>Lewis</surname><given-names>SJ</given-names></name></person-group><article-title>Tricks of the mind: visual hallucinations as disorders of attention</article-title><source>Progress in neurobiology</source><year>2014</year><volume>116</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">24525149</pub-id></element-citation></ref><ref id="R69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solla</surname><given-names>P</given-names></name><name><surname>Masala</surname><given-names>C</given-names></name><name><surname>Pinna</surname><given-names>I</given-names></name><name><surname>Ercoli</surname><given-names>T</given-names></name><name><surname>Loy</surname><given-names>F</given-names></name><name><surname>Orofino</surname><given-names>G</given-names></name><name><surname>Fadda</surname><given-names>L</given-names></name><name><surname>Defazio</surname><given-names>G</given-names></name></person-group><article-title>Frequency and Determinants of Olfactory Hallucinations in Parkinson’s Disease Patients</article-title><source>Brain sciences</source><year>2021</year><volume>11</volume><issue>7</issue><fpage>841</fpage><pub-id pub-id-type="pmcid">PMC8301996</pub-id><pub-id pub-id-type="pmid">34202903</pub-id><pub-id pub-id-type="doi">10.3390/brainsci11070841</pub-id></element-citation></ref><ref id="R70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name></person-group><article-title>Mechanism of action of pimavanserin in Parkinson’s disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors</article-title><source>CNS Spectr</source><year>2016a</year><volume>21</volume><issue>4</issue><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">27503570</pub-id></element-citation></ref><ref id="R71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stahl</surname><given-names>SM</given-names></name></person-group><article-title>Parkinson’s disease psychosis as a serotonin-dopamine imbalance syndrome</article-title><source>CNS Spectr</source><year>2016b</year><volume>21</volume><issue>5</issue><fpage>355</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">27686027</pub-id></element-citation></ref><ref id="R72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stebbins</surname><given-names>GT</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Bangen</surname><given-names>KJ</given-names></name><name><surname>Turner</surname><given-names>DA</given-names></name><name><surname>Glover</surname><given-names>GH</given-names></name><name><surname>Gabrieli</surname><given-names>JDE</given-names></name></person-group><article-title>Altered cortical visual processing in PD with hallucinations - An fMRI study [Article]</article-title><source>Neurology</source><year>2004</year><volume>63</volume><issue>8</issue><fpage>1409</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">15505157</pub-id></element-citation></ref><ref id="R73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veronese</surname><given-names>M</given-names></name><name><surname>Zanotti-Fregonara</surname><given-names>P</given-names></name><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Bertoldo</surname><given-names>A</given-names></name><name><surname>Innis</surname><given-names>RB</given-names></name><name><surname>Turkheimer</surname><given-names>FE</given-names></name></person-group><article-title>Measuring specific receptor binding of a PET radioligand in human brain without pharmacological blockade: The genomic plot</article-title><source>Neuroimage</source><year>2016</year><volume>130</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmcid">PMC4983715</pub-id><pub-id pub-id-type="pmid">26850512</pub-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.01.058</pub-id></element-citation></ref><ref id="R74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vértes</surname><given-names>PE</given-names></name><name><surname>Rittman</surname><given-names>T</given-names></name><name><surname>Whitaker</surname><given-names>KJ</given-names></name><name><surname>Romero-Garcia</surname><given-names>R</given-names></name><name><surname>Váša</surname><given-names>F</given-names></name><name><surname>Kitzbichler</surname><given-names>MA-O</given-names></name><name><surname>Wagstyl</surname><given-names>K</given-names></name><name><surname>Fonagy</surname><given-names>P</given-names></name><name><surname>Dolan</surname><given-names>RJ</given-names></name><name><surname>Jones</surname><given-names>PB</given-names></name><name><surname>Goodyer</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Gene transcription profiles associated with inter-modular hubs and connection distance in human functional magnetic resonance imaging networks</article-title><comment>LID LID-20150362. (1471-2970 (Electronic))</comment><pub-id pub-id-type="pmcid">PMC5003862</pub-id><pub-id pub-id-type="pmid">27574314</pub-id><pub-id pub-id-type="doi">10.1098/rstb.2015.0362</pub-id></element-citation></ref><ref id="R75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vignando</surname><given-names>M</given-names></name><name><surname>ffytche</surname><given-names>D</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>PH</given-names></name><name><surname>Chung</surname><given-names>SJ</given-names></name><name><surname>Weil</surname><given-names>RS</given-names></name><name><surname>Hu</surname><given-names>MT</given-names></name><name><surname>Mackay</surname><given-names>CE</given-names></name><name><surname>Griffanti</surname><given-names>L</given-names></name><name><surname>Pins</surname><given-names>D</given-names></name><name><surname>Dujardin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations: a mega-analysis</article-title><source>medRxiv</source><year>2021</year><elocation-id>2021.2002.2017.21251558</elocation-id><pub-id pub-id-type="doi">10.1101/2021.02.17.21251558</pub-id></element-citation></ref><ref id="R76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Lian</surname><given-names>B</given-names></name><etal/></person-group><article-title>Serotonin-1A receptor alterations in depression: a meta-analysis of molecular imaging studies</article-title><source>BMC Psychiatry</source><year>2016</year><volume>16</volume><issue>1</issue><fpage>319</fpage><pub-id pub-id-type="pmcid">PMC5022168</pub-id><pub-id pub-id-type="pmid">27623971</pub-id><pub-id pub-id-type="doi">10.1186/s12888-016-1025-0</pub-id></element-citation></ref><ref id="R77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>H</given-names></name><name><surname>Senda</surname><given-names>J</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><name><surname>Atsuta</surname><given-names>N</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Tsuboi</surname><given-names>T</given-names></name><name><surname>Katsuno</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Hirayama</surname><given-names>M</given-names></name></person-group><article-title>Cortical and subcortical brain atrophy in Parkinson’s disease with visual hallucination</article-title><source>Movement Disorders</source><year>2013</year><volume>28</volume><issue>12</issue><fpage>1732</fpage><lpage>1736</lpage><pub-id pub-id-type="pmid">24150865</pub-id></element-citation></ref><ref id="R78"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Shea</surname><given-names>B</given-names></name><name><surname>O’Connell</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Welch</surname><given-names>V</given-names></name><name><surname>Losos</surname><given-names>M</given-names></name><name><surname>Tugwell</surname><given-names>P</given-names></name></person-group><source>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses</source><publisher-name>Oxford</publisher-name><year>2000</year></element-citation></ref><ref id="R79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name></person-group><article-title>Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study</article-title><source>Lancet Neurol</source><year>2005</year><volume>4</volume><issue>10</issue><fpage>605</fpage><lpage>610</lpage><pub-id pub-id-type="pmid">16168928</pub-id></element-citation></ref><ref id="R80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>NL</given-names></name><name><surname>Chang</surname><given-names>RSK</given-names></name><name><surname>Cheung</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>S</given-names></name><name><surname>Lau</surname><given-names>KK</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Rowe</surname><given-names>JB</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Mak</surname><given-names>HKF</given-names></name><name><surname>Chua</surname><given-names>SE</given-names></name><name><surname>Ho</surname><given-names>SL</given-names></name><etal/></person-group><article-title>The Default Mode Network is Disrupted in Parkinson’s Disease with Visual Hallucinations</article-title><source>Human Brain Mapping</source><year>2014</year><volume>35</volume><issue>11</issue><fpage>5658</fpage><lpage>5666</lpage><comment>[Article]</comment><pub-id pub-id-type="pmcid">PMC4657500</pub-id><pub-id pub-id-type="pmid">24985056</pub-id><pub-id pub-id-type="doi">10.1002/hbm.22577</pub-id></element-citation></ref><ref id="R81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>NL</given-names></name><name><surname>Cheung</surname><given-names>C</given-names></name><name><surname>Pang</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>RSK</given-names></name><name><surname>Lau</surname><given-names>KK</given-names></name><name><surname>Suckling</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Mak</surname><given-names>HKF</given-names></name><name><surname>Chua</surname><given-names>SE</given-names></name><name><surname>Ho</surname><given-names>SL</given-names></name><name><surname>McAlonan</surname><given-names>GM</given-names></name></person-group><article-title>Multimodal MRI of the hippocampus in Parkinson’s disease with visual hallucinations</article-title><source>Brain Structure &amp; Function</source><year>2016</year><volume>221</volume><issue>1</issue><fpage>287</fpage><lpage>300</lpage><comment>[Article]</comment><pub-id pub-id-type="pmcid">PMC4720723</pub-id><pub-id pub-id-type="pmid">25287513</pub-id><pub-id pub-id-type="doi">10.1007/s00429-014-0907-5</pub-id></element-citation></ref><ref id="R82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yunusa</surname><given-names>I</given-names></name><name><surname>El Helou</surname><given-names>ML</given-names></name><name><surname>Alsahali</surname><given-names>S</given-names></name></person-group><article-title>Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis [Mini Review]</article-title><source>Frontiers in Pharmacology</source><year>2020</year><volume>11</volume><pub-id pub-id-type="pmcid">PMC7054448</pub-id><pub-id pub-id-type="pmid">32174828</pub-id><pub-id pub-id-type="doi">10.3389/fphar.2020.00087</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>PRISMA flowchart showing study selection procedures.</title></caption><graphic xlink:href="EMS157280-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>A) Overlapping peak areas (shown in purple) with grey matter loss in PD psychosis patients unadjusted (red) and adjusted for LEDD (expressed in mg/day) (blue) as covariate (uncorrected). This is indicated by the red and blue colour bars on which represent the T threshold of the voxels within the map. B) Overlapping peak areas (shown in yellow) with grey matter loss in PD psychosis patients unadjusted (red) and adjusted for cognitive scores (green) as covariate (uncorrected). This is indicated by the red and green colours bar on the right-hand side of the figure which represent the T threshold of the voxels within the map. The left side of the brain is shown on the right side of these brain images.</p></caption><graphic xlink:href="EMS157280-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Gene expression density of 5-HT2a (A), 5-HT1a (B) receptors in cortical and subcortical regions, and Hedges’ g effect size in cortical and subcortical regions (C) derived from the covariate meta-analysis (adjusted for LEDD) results showing decreased grey matter in PDP patients compared to PDnP patients (PDP &lt; PDnP), parcellated across the 78 brain regions of the Desikan-Killiany atlas (<xref ref-type="bibr" rid="R17">Desikan et al., 2006</xref>). On the right-hand side, scatterplots showing the relationship between 5-HT2a (D) and 5-HT1a (E) with Hedges’ g effect-size estimates of grey matter volume adjusted for LEDD in PDP patients compared to PDnP patients (the regression lines are adjusted for all the predictors).</p></caption><graphic xlink:href="EMS157280-f003"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Study description with statistics (mean, unless otherwise specified) presented for each patient group (PDP patients; PDnP patients).</title><p>Number of patients for each group are presented alongside gender (males, M; females, F), years of education, scores on cognitive outcomes. Clinical variables of interest are also reported, e.g., motor symptoms (according to the MDS-UPDRS), PD medications (expressed in mean daily mg where available), and depression scores where available.</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="center" valign="top">Study</th><th align="center" valign="top">PDP patient</th><th align="center" valign="top">PDnP patients</th><th align="center" valign="top">Definition of PD psychosis</th><th align="center" valign="top">Age (mean years)</th><th align="center" valign="top">Educations (in years)</th><th align="center" valign="top">Cognitive outcome</th><th align="center" valign="top">PD onset (years)</th><th align="center" valign="top">PD duration</th><th align="center" valign="top">MDS-UPDRS part III scores (mean)</th><th align="center" valign="top">PD medications (mg/day)</th><th align="center" valign="top">Depression scores</th></tr></thead><tbody><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R8">Bejr-Kasem et al. (2019)</xref>, Spain Scanner: Philips, 3.0 T</td><td align="center" valign="top">18 (10M, 8F)</td><td align="center" valign="top">14 (10M, 4F)</td><td align="center" valign="top">PD patients included if VH remained stable during the 3 months before inclusion in the study</td><td align="center" valign="top">70.4; 65.8</td><td align="center" valign="top">12.5; 11.6</td><td align="center" valign="top">PD-CRS, 91.9; 92.9</td><td align="center" valign="top">NR</td><td align="center" valign="top">5.2; 4 (years)</td><td align="center" valign="top">21.9; 25.8</td><td align="center" valign="top">LEDD 697.2 mg; 601.1 mg</td><td align="center" valign="top">HADS-D 2.2; 3.3</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R38">Lee et al. (2017)</xref>, South Korea Scanner: Philips, 3.0 T</td><td align="center" valign="top">10 (7M, 3F)</td><td align="center" valign="top">21 (9M, 11F)</td><td align="center" valign="top">VH definition was based on consensus, with VH persistent for at least 3 months</td><td align="center" valign="top">69.4; 66.2</td><td align="center" valign="top">NR</td><td align="center" valign="top">MMSE 27.6; 28.2</td><td align="center" valign="top">62.2; 59.3</td><td align="center" valign="top">7.2; 7 (years)</td><td align="center" valign="top">22.5; 16.4</td><td align="center" valign="top">LEDD1031. 2 mg; 805.2 mg</td><td align="center" valign="top">GDS 16.6; 15.5</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R53">Pagonabarraga et al. (2014)</xref>, Spain Scanner: General Electric, 1.5 T</td><td align="center" valign="top">17 (NR)</td><td align="center" valign="top">29 (NR)</td><td align="center" valign="top">Presence of VH was assessed with the MDS-UPDRS part 1 using item 1.2</td><td align="center" valign="top">64.1; 66.3</td><td align="center" valign="top">11.1; 9.2</td><td align="center" valign="top">PD-CRS 87.2; 90.3</td><td align="center" valign="top">53.1; 58.7</td><td align="center" valign="top">9.8; 7.3 (years)</td><td align="center" valign="top">21.7; 18.6</td><td align="center" valign="top">LEDD 996 mg; 816 mg</td><td align="center" valign="top">HADS-D 5.2; 4.4</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R37">Lawn &amp; ffytche (2021)</xref>, UK Scanner: General Electric, 1.5 T</td><td align="center" valign="top">7 (3M, 4F)</td><td align="center" valign="top">9 (7M, 2F)</td><td align="center" valign="top">PD patients with a range of complex hallucinations as well as illusions, passage, and presence hallucinations</td><td align="center" valign="top">68.9; 65.1</td><td align="center" valign="top">NR</td><td align="center" valign="top">MMSE 26.9; 29.7</td><td align="center" valign="top">NR</td><td align="center" valign="top">8.71; 5.8 (years)</td><td align="center" valign="top">40; 25.6<xref ref-type="table-fn" rid="TFN2">*</xref></td><td align="center" valign="top">L-dopa n=2, L-dopa + DA n=4, DA=1; L-dopa n=2, L-dopa + DA, n=4, DA, n=3 <xref ref-type="table-fn" rid="TFN1">†</xref></td><td align="center" valign="top"/></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R56">Ramirez-Ruiz et al. (2007)</xref>, Spain Scanner: General Electric, 1.5 T</td><td align="center" valign="top">18 (7M, 11F)</td><td align="center" valign="top">20 (8M, 12F)</td><td align="center" valign="top">NPI (hallucination item)</td><td align="center" valign="top">NR</td><td align="center" valign="top">7.6; 7.5</td><td align="center" valign="top">MMSE 27; 29.1</td><td align="center" valign="top">NR</td><td align="center" valign="top">12.6; 10.6 (years)</td><td align="center" valign="top">29.3; 24.5</td><td align="center" valign="top">Levodopa daily dose 723.6 mg; 647.5 mg</td><td align="center" valign="top">Hamilton 6.7; 3.6</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R8">Bejr-Kasem et al. (2021)</xref>, Spain Scanner: PPMI data</td><td align="center" valign="top">40 (23M, 17F)</td><td align="center" valign="top">84 (25M, 59F)</td><td align="center" valign="top">Presence of VH was assessed with the MDS-UPDRS part 1 using item 1.2</td><td align="center" valign="top">60.1; 60.7</td><td align="center" valign="top">14.5; 15.6</td><td align="center" valign="top">MoCA 27.7; 27.3</td><td align="center" valign="top">NR</td><td align="center" valign="top">7.2; 6.7 (months)</td><td align="center" valign="top">20.7; 19.8</td><td align="center" valign="top">LEDD 0 mg; 0 mg</td><td align="center" valign="top">GDS 2.1; 2.2</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R77">Watanabe et al. (2013)</xref>, <bold>Japan</bold> Scanner: Siemens, 3.0 T</td><td align="center" valign="top">13 (7M, 6F)</td><td align="center" valign="top">13 (5M, 8F)</td><td align="center" valign="top">Presence of VH was assessed with the MDS-UPDRS part 1 using item 1.2</td><td align="center" valign="top">66.6; 63.6</td><td align="center" valign="top">12.7; 12.2</td><td align="center" valign="top">MMSE 27.9; 29</td><td align="center" valign="top">56.9; 53.6</td><td align="center" valign="top">10; 10 (years)</td><td align="center" valign="top">23.4; 28.6</td><td align="center" valign="top">LEDD 411.5 mg; 361 mg</td><td align="center" valign="top">BDI 21.7; 9</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R21">Firbank et al. (2018)</xref>, UK Scanner: Philips, 3.0 T</td><td align="center" valign="top">17 (13M, 4F)</td><td align="center" valign="top">19 (17M, 2F)</td><td align="center" valign="top">NPI (hallucination item)</td><td align="center" valign="top">75.5; 72.3</td><td align="center" valign="top">11.6; 11.1</td><td align="center" valign="top">MMSE 23.1; 25.6</td><td align="center" valign="top">NR</td><td align="center" valign="top">11; 9.6 (years)</td><td align="center" valign="top">55.9; 34.7</td><td align="center" valign="top">Levodopa in 24h 717.3 mg; 673. 5 mg</td><td align="center" valign="top">NR</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R64">Shin et al. (2012)</xref>, <bold>South Korea</bold> Scanner: Philips, 3.0 T</td><td align="center" valign="top">46 (23M, 23F)</td><td align="center" valign="top">64 (26M, 38F)</td><td align="center" valign="top">Formed VH defined as “repetitive involuntary images of people, animal or objects that were experienced as real during the waking state but for which there was no objective reality”, and NPI</td><td align="center" valign="top">71.3; 70.7</td><td align="center" valign="top">8.3; 8.4</td><td align="center" valign="top">MMSE 25.2; 25.7</td><td align="center" valign="top">NR</td><td align="center" valign="top">3.3; 2.8 (months)</td><td align="center" valign="top">24.1; 21.6</td><td align="center" valign="top">LEDD 482.4 mg; 501.4 mg</td><td align="center" valign="top">NR</td></tr><tr><td align="left" valign="top"><xref ref-type="bibr" rid="R26">Goldman et al. (2014)</xref>, US Scanner: General Electric, 1.5 T</td><td align="center" valign="top">25 (17M, 8F)</td><td align="center" valign="top">25 (18M, 7F)</td><td align="center" valign="top">NINDS-NIMH criteria and the MDS-UPDRS part 1 using item 1.2</td><td align="center" valign="top">74.8; 75.4</td><td align="center" valign="top">15.4; 15.7</td><td align="center" valign="top">MMSE 23.9; 25.1</td><td align="center" valign="top">NR</td><td align="center" valign="top">13.1; 10.8 (years)</td><td align="center" valign="top">39; 43.5</td><td align="center" valign="top">LEDD 808.3 mg; 787.8 mg</td><td align="center" valign="top">NR</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>†</label><p id="P36">Number of patients on PD medications</p></fn><fn id="TFN2"><label>*</label><p id="P37">UPDRS combined scores for part III and IV</p><p id="P38">BDI: Beck Depression Inventory; GDS: Geriatric Depression Scale; HADS-D: Hospital Anxiety and Depression Scale – depression item; LEDD: Levodopa equivalent daily dose; MDS-UPDRS: Movement Disorder Society – Unified Parkinson’s Disease Rating Scale; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; NINDS-NIMH: National Institute of Neurological Disorders and Stroke – National Institute of Mental Health; NPI: Neuropsychiatry Inventory; NR: None reported; PD-CRS: Parkinson’s Disease – Cognitive Rating Scale; VH: Visual hallucinations.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Peak coordinates showing greater grey matter loss in PDP patients compared to PDnP patients, alongside number of voxels, Z scores, and associated <italic>p</italic> value (uncorrected), <italic>I</italic><sup>2</sup> (which indicates the magnitude of between-study heterogeneity as a proportion of total variability within each peak), and publication bias expressed as Egger’s test <italic>p</italic> value.</p></caption><table frame="hsides" rules="rows"><thead><tr><th align="center" valign="top" colspan="2">Peak regions</th><th align="center" valign="top" colspan="3">MNI coordinates</th><th align="center" valign="top">Number of voxels</th><th align="center" valign="top">Z score</th><th align="center" valign="top">p value</th><th align="center" valign="top"><italic>F</italic></th><th align="center" valign="top">Egger’s test <italic>p</italic> value</th></tr><tr><th align="left" valign="top" colspan="2"/><th align="center" valign="top">x</th><th align="center" valign="top">y</th><th align="center" valign="top">z</th><th align="center" valign="top"/><th align="center" valign="top"/><th align="center" valign="top"/><th align="center" valign="top"/><th align="center" valign="top"/></tr></thead><tbody><tr><td align="left" valign="top" colspan="2"><bold>PDP &lt; PDnP</bold></td><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right precuneus (extending to left precuneus, bilateral cuneus)</td><td align="center" valign="top">10</td><td align="center" valign="top">-66</td><td align="center" valign="top">42</td><td align="center" valign="top">1059</td><td align="center" valign="top">-2.990</td><td align="center" valign="top">0.001</td><td align="center" valign="top">1.729%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior parietal gyrus (extending to the left angular gyrus, and supramarginal gyrus)</td><td align="center" valign="top">-48</td><td align="center" valign="top">-52</td><td align="center" valign="top">40</td><td align="center" valign="top">296</td><td align="center" valign="top">-2.449</td><td align="center" valign="top">0.007</td><td align="center" valign="top">0.849%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right inferior parietal gyrus (extending to right angular gyrus)</td><td align="center" valign="top">46</td><td align="center" valign="top">-56</td><td align="center" valign="top">44</td><td align="center" valign="top">277</td><td align="center" valign="top">-2.225</td><td align="center" valign="top">0.013</td><td align="center" valign="top">27.631%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior occipital gyrus</td><td align="center" valign="top">-38</td><td align="center" valign="top">-84</td><td align="center" valign="top">-8</td><td align="center" valign="top">262</td><td align="center" valign="top">-2.627</td><td align="center" valign="top">0.004</td><td align="center" valign="top">11.411%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right middle temporal gyrus (extending to right inferior temporal gyrus)</td><td align="center" valign="top">52</td><td align="center" valign="top">-2</td><td align="center" valign="top">-30</td><td align="center" valign="top">225</td><td align="center" valign="top">-2.664</td><td align="center" valign="top">0.003</td><td align="center" valign="top">9.657%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right cerebellum, hemispheric lobule VIII (extending to lobule IX)</td><td align="center" valign="top">18</td><td align="center" valign="top">-52</td><td align="center" valign="top">-54</td><td align="center" valign="top">92</td><td align="center" valign="top">-1.983</td><td align="center" valign="top">0.023</td><td align="center" valign="top">16.551%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left median cingulate / paracingulate gyrus (extending to the right median cingulate and paracingulate gyrus)</td><td align="center" valign="top">-4</td><td align="center" valign="top">-8</td><td align="center" valign="top">46</td><td align="center" valign="top">57</td><td align="center" valign="top">-2.032</td><td align="center" valign="top">0.021</td><td align="center" valign="top">5.906%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior temporal gyrus</td><td align="center" valign="top">-46</td><td align="center" valign="top">-8</td><td align="center" valign="top">-32</td><td align="center" valign="top">42</td><td align="center" valign="top">-1.989</td><td align="center" valign="top">0.023</td><td align="center" valign="top">0.517%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right supramarginal gyrus</td><td align="center" valign="top">58</td><td align="center" valign="top">-38</td><td align="center" valign="top">30</td><td align="center" valign="top">32</td><td align="center" valign="top">-2.179</td><td align="center" valign="top">0.014</td><td align="center" valign="top">8.127%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right lingual gyrus (extending to the calcarine fissure)</td><td align="center" valign="top">10</td><td align="center" valign="top">-54</td><td align="center" valign="top">8</td><td align="center" valign="top">29</td><td align="center" valign="top">-2.186</td><td align="center" valign="top">0.014</td><td align="center" valign="top">1.229%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left postcentral gyrus (extending to left inferior parietal gyrus)</td><td align="center" valign="top">-40</td><td align="center" valign="top">-36</td><td align="center" valign="top">44</td><td align="center" valign="top">22</td><td align="center" valign="top">-2.163</td><td align="center" valign="top">0.015</td><td align="center" valign="top">5.246%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top" colspan="2"><bold>PDP &lt; PDnP (with LEDD as covariate)</bold></td><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right precuneus (extending to the left precuneus and bilateral cuneus)</td><td align="center" valign="top">6</td><td align="center" valign="top">-62</td><td align="center" valign="top">46</td><td align="center" valign="top">1084</td><td align="center" valign="top">-2.952</td><td align="center" valign="top">0.001</td><td align="center" valign="top">5.656%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left angular gyrus (extending to left inferior parietal gyrus)</td><td align="center" valign="top">-50</td><td align="center" valign="top">-56</td><td align="center" valign="top">34</td><td align="center" valign="top">389</td><td align="center" valign="top">-2.596</td><td align="center" valign="top">0.004</td><td align="center" valign="top">2.443%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right inferior temporal gyrus (extending to the right middle temporal gyrus and right fusiform)</td><td align="center" valign="top">50</td><td align="center" valign="top">-10</td><td align="center" valign="top">-30</td><td align="center" valign="top">353</td><td align="center" valign="top">-2.921</td><td align="center" valign="top">0.001</td><td align="center" valign="top">3.859%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left middle occipital gyrus (extending to the inferior occipital gyrus)</td><td align="center" valign="top">-34</td><td align="center" valign="top">-84</td><td align="center" valign="top">6</td><td align="center" valign="top">315</td><td align="center" valign="top">-2.902</td><td align="center" valign="top">0.001</td><td align="center" valign="top">1.279%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right inferior parietal gyrus (extending to the right angular gyrus)</td><td align="center" valign="top">40</td><td align="center" valign="top">-56</td><td align="center" valign="top">48</td><td align="center" valign="top">304</td><td align="center" valign="top">-2.525</td><td align="center" valign="top">0.005</td><td align="center" valign="top">3.747%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left median cingulate/paracingulate gyrus (extending to the right median cingulate/paracingulate gyrus and left supplementary motor area)</td><td align="center" valign="top">2</td><td align="center" valign="top">12</td><td align="center" valign="top">41</td><td align="center" valign="top">144</td><td align="center" valign="top">-2.206</td><td align="center" valign="top">0.013</td><td align="center" valign="top">2.152</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right supramarginal gyrus</td><td align="center" valign="top">56</td><td align="center" valign="top">-40</td><td align="center" valign="top">28</td><td align="center" valign="top">117</td><td align="center" valign="top">-.2693</td><td align="center" valign="top">0.003</td><td align="center" valign="top">3.343%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right lingual gyrus (extending to cerebellum, vermis lobule IV/V)</td><td align="center" valign="top">10</td><td align="center" valign="top">-52</td><td align="center" valign="top">6</td><td align="center" valign="top">105</td><td align="center" valign="top">-2.345</td><td align="center" valign="top">0.009</td><td align="center" valign="top">1.418%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right middle occipital gyrus</td><td align="center" valign="top">44</td><td align="center" valign="top">-76</td><td align="center" valign="top">8</td><td align="center" valign="top">104</td><td align="center" valign="top">-2.203</td><td align="center" valign="top">0.013</td><td align="center" valign="top">0.968%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior temporal gyrus</td><td align="center" valign="top">-46</td><td align="center" valign="top">-10</td><td align="center" valign="top">-26</td><td align="center" valign="top">95</td><td align="center" valign="top">-2.270</td><td align="center" valign="top">0.011</td><td align="center" valign="top">0.526%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right fusiform gyrus (extending to the right cerebellum, hemispheric lobule IV/V)</td><td align="center" valign="top">24</td><td align="center" valign="top">-36</td><td align="center" valign="top">-22</td><td align="center" valign="top">85</td><td align="center" valign="top">-2.275</td><td align="center" valign="top">0.011</td><td align="center" valign="top">8.312</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left temporal pole</td><td align="center" valign="top">-44</td><td align="center" valign="top">8</td><td align="center" valign="top">-40</td><td align="center" valign="top">47</td><td align="center" valign="top">-2.340</td><td align="center" valign="top">0.009</td><td align="center" valign="top">0.196%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior parietal gyrus (extending to the left postcentral gyrus)</td><td align="center" valign="top">-38</td><td align="center" valign="top">-38</td><td align="center" valign="top">44</td><td align="center" valign="top">39</td><td align="center" valign="top">-2.538</td><td align="center" valign="top">0.005</td><td align="center" valign="top">7.669%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left cerebellum hemispheric lobule VI (extending to the left lingual gyrus)</td><td align="center" valign="top">-10</td><td align="center" valign="top">-78</td><td align="center" valign="top">-16</td><td align="center" valign="top">39</td><td align="center" valign="top">-2.197</td><td align="center" valign="top">0.014</td><td align="center" valign="top">3.506%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left supplementary motor area (extending to the left median cingulate/paracingulate gyrus)</td><td align="center" valign="top">-4</td><td align="center" valign="top">-12</td><td align="center" valign="top">48</td><td align="center" valign="top">26</td><td align="center" valign="top">-2.233</td><td align="center" valign="top">0.012</td><td align="center" valign="top">2.144%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right calcarine fissure (extending to the right lingual gyrus)</td><td align="center" valign="top">10</td><td align="center" valign="top">-86</td><td align="center" valign="top">-2</td><td align="center" valign="top">21</td><td align="center" valign="top">-2.082</td><td align="center" valign="top">0.019</td><td align="center" valign="top">0.047%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/></tr><tr><td align="left" valign="top" colspan="2"><bold>PDP &lt; PDnP (with cognitive scores as covariate)</bold></td><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/><td align="center" valign="top"/></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right precuneus (extending to left precuneus, bilateral cuneus)</td><td align="center" valign="top">8</td><td align="center" valign="top">-64</td><td align="center" valign="top">38</td><td align="center" valign="top">1186</td><td align="center" valign="top">-3.287</td><td align="center" valign="top">&lt;0.001</td><td align="center" valign="top">0.002%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior parietal gyrus (extending to the left angular gyrus)</td><td align="center" valign="top">-48</td><td align="center" valign="top">-52</td><td align="center" valign="top">38</td><td align="center" valign="top">467</td><td align="center" valign="top">-2.666</td><td align="center" valign="top">0.003</td><td align="center" valign="top">0.001%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right inferior temporal gyrus (extending to the right middle temporal gyrus)</td><td align="center" valign="top">52</td><td align="center" valign="top">-6</td><td align="center" valign="top">-30</td><td align="center" valign="top">304</td><td align="center" valign="top">-3.010</td><td align="center" valign="top">0.001</td><td align="center" valign="top">0.017%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right inferior parietal gyrus (extending to right angular gyrus)</td><td align="center" valign="top">44</td><td align="center" valign="top">-58</td><td align="center" valign="top">44</td><td align="center" valign="top">280</td><td align="center" valign="top">-2.966</td><td align="center" valign="top">0.001</td><td align="center" valign="top">0.010%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior occipital gyrus (extending to the left middle occipital gyrus)</td><td align="center" valign="top">-38</td><td align="center" valign="top">-86</td><td align="center" valign="top">-10</td><td align="center" valign="top">252</td><td align="center" valign="top">-2.508</td><td align="center" valign="top">0.006</td><td align="center" valign="top">0.002%</td><td align="center" valign="top">n.s</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right lingual gyrus (extending to the cerebellum, vermic lobule IV/V and VI and to the right precuneus)</td><td align="center" valign="top">10</td><td align="center" valign="top">-54</td><td align="center" valign="top">6</td><td align="center" valign="top">234</td><td align="center" valign="top">-2.483</td><td align="center" valign="top">0.006</td><td align="center" valign="top">0.001%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left postcentral gyrus (extending to the left precuneus, and left superior parietal gyrus)</td><td align="center" valign="top">-20</td><td align="center" valign="top">-42</td><td align="center" valign="top">66</td><td align="center" valign="top">116</td><td align="center" valign="top">-2.358</td><td align="center" valign="top">0.009</td><td align="center" valign="top">0.000%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left inferior temporal gyrus (extending to the left middle temporal gyrus)</td><td align="center" valign="top">-44</td><td align="center" valign="top">-8</td><td align="center" valign="top">-30</td><td align="center" valign="top">86</td><td align="center" valign="top">-2.344</td><td align="center" valign="top">0.009</td><td align="center" valign="top">0.002%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Left median cingulate/paracingulate gyri (extending to the right median cingulate/paracingulate gyri)</td><td align="center" valign="top">-2</td><td align="center" valign="top">-4</td><td align="center" valign="top">42</td><td align="center" valign="top">60</td><td align="center" valign="top">-2.149</td><td align="center" valign="top">0.016</td><td align="center" valign="top">0.001%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right superior parietal gyrus</td><td align="center" valign="top">26</td><td align="center" valign="top">-62</td><td align="center" valign="top">58</td><td align="center" valign="top">28</td><td align="center" valign="top">-2.030</td><td align="center" valign="top">0.021</td><td align="center" valign="top">0.002%</td><td align="center" valign="top">n.s.</td></tr><tr><td align="left" valign="top"> </td><td align="left" valign="top">Right fusiform gyrus</td><td align="center" valign="top">30</td><td align="center" valign="top">-42</td><td align="center" valign="top">-18</td><td align="center" valign="top">17</td><td align="center" valign="top">-1.794</td><td align="center" valign="top">0.036</td><td align="center" valign="top">0.117%</td><td align="center" valign="top">n.s.</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p id="P39">n.s.: non-significant</p></fn></table-wrap-foot></table-wrap></floats-group></article>